


DIABETES

The Journal of the American Diabetes Association

INDEX

BY SUBJECT AND AUTHOR




VOLUME 8

1959

110846

Copyright 1960, by American Diabetes Association, Inc.



SUBJECT INDEX 1959

This index covers all reading matter in Volume 8 of DIABETES. Entries marked with an asterisk (*) indicate material which appeared in the ABSTRACTS only. The author index appears on page 23.

A

ABC. *See* Amylbiguanide; Isoamylbiguanide

ABORTION

See also Pregnancy, fetal death
and male diabetes, *328
and unsuspected prediabetes, *330

ACETATE

fatty acids synthesis, 341
and coenzyme A, 68
after fasting, 115
ketogenic potency, *76
and linolenate β -oxidation, 231
protein uptake, 391
pyruvate conversion to, 341

ACETOACETIC ACID

determination method, *70
diaphragm and muscle uptake, *479
glucose-cyclo-, and estrogen therapy, *242
production mechanism, *76, 341

ACETONE BODIES. *See* Ketone bodies

ACID. *See* specific acid

ACIDOSIS, DIABETIC

See also Ketoacidosis
abdominal pain, *399
presenting symptom, 290
and biguanides, 154, *243
and blood pepsinogen levels, 91
bone chloride and water content, *486
and emotional disturbance, 372, 380
and glucagon, 91
and hydrannios, *242
and insulin requirements, *73, 154
after pancreatectomy, *400
and islet cell changes, *75
and ribose infusion, 456
self-destructive behavior, 379-381
and surgery, *239, *399, *400
and therapy selection, *480, *488
transient renal insufficiency, *243

ACTH. *See* Adrenocorticotrophic hormone

ADAPTATION

and adrenal cortex, 348
behavior patterns, 358-359
in diabetes, 359-363, 372
pancreas, to cortisone, *484

ADDISON'S DISEASE, 357

and cortisone, 347
diabetes coexistence, 347, 348, *482

hypoglycemia, 342, *401
and ketone bodies, 140, 346
nitrogen excretion, 344
and sulfonyleurea compounds, *241
and insulin sensitivity, 342

ADENOHYPOPHYSIS

adrenocorticotrophic hormone secretion, 357
blood supply, 355-356
and epinephrine, 356
hypothalamic control, 352-357
removal. *See* Hypophysectomy
stimulation, 356

ADRENAL GLAND

and adaptation, 348
cortex, *239
and carbohydrate metabolism, 105-110, 342-343, 345
carcinoma, *157
and hypoglycemia, *157, *482
spontaneous, classification, *487
and islet cell changes, *76, *241
and metabolism of baboon, *241
and nitrogen excretion, 344, 345, 346

in obesity, *330
and protein metabolism, 345
and thyrotoxicosis, *75

and diabetes, 337-349
after dodecamethylenediguanidine, *239
and glucose, 200-203, 342-344, *402
utilization, *320, 346-347
hormones, 15-16, 59-61, 132-141, 339-342

See also specific hormones
hyperfunction. *See* Cushing's disease
and hypophysectomy, 106-110, 199-204
insufficiency. *See* Addison's disease
and insulin, *74, *158, *329, *330, 348, *483

in nitrogen loss, 57-61
and ketogenesis after pancreatectomy, 132-141

medulla, 199-204, *239, *330
and phenethylbiguanide, *239, 274, 277

-pituitary axis, 139
in pregnancy, 15-16, 19, 49
and tolbutamide response, 199-204

ADRENALECTOMY

and adrenocorticotrophic hormone, 136, 139, 140, 343
and carbohydrate metabolism, 105-110
and cortisone, 135-136, 139, 140
and fatty acid synthesis, 347

and glucose, 109, *320
blood content, 201, 342-344, *402, *403
and glucocorticoids, 346, 347
intracellular muscle, *403
lymph, *402
plasma concentration, 107
and growth hormone response, 109, 140, *320
and hypophysectomy, 106-110
and tolbutamide, 199-204
and insulin sensitivity, 106, 342
and ketone bodies, 109
after pancreatectomy, 132-141
and lipogenesis in adipose tissue, 347
and liver blood flow after insulin, *159
urinary nitrogen excretion, 346
and vascular lesions, *72

ADRENALIN. *See* Epinephrine

ADRENOCORTICOTROPHIC HORMONE

after adrenalectomy, 136, 139, 140, 343
and alkalosis, *323
and carbohydrate metabolism, 343
and carbutamide, *399
and glucose, 59-61
disappearance, *238, *326
and glycogen, *76, 343
and growth hormone, 59-61, *76
after hypophysectomy, 140
and insulin, *74, *322, *326, 430
and ketogenesis, 136, 139, 140, 343
in obesity, *330
after pancreatectomy, 59-61, 139, 140
secretion, 353-357
and compound D, 354, 356
and glucocorticoids, 22
and steroid diabetes, *329
and vascular changes, 347-348

AGE

and arteriosclerosis, 301-302, 304
and career choice, 147
and Charcot joint, 194
and chlorpropamide therapy, 3-4, 366, 367, 370
and cholesterol levels, *331
and total lipid levels, *486
and diabetes. *See* Diabetes mellitus, childhood; in elderly; juvenile
and diguanides, 275, 277, *403
employment, 144, 147
and formamidinyliminurea therapy, *324
and Glipasol, *481
and impotence, *243, *328

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

July-August, 251-336

March-April, 83-166

September-October, 337-416

May-June, 167-250

November-December, 417-496

SUBJECT INDEX 1959

- and insulin requirement, 196
and longevity, 173
maternal, and fetal survival, 15
and mucopolysaccharides, metabolism,
*321
and nonesterified fatty acid, 453
and oral hypoglycemics, 3-4, *324,
329, 366, 367, 378, *403
See also specific substances
and pancreatic islets, 84-86
alpha-beta cell ratios, *240, *483
and phenethylbiguanide, 275, 277
and suicidal behavior, 379, 380-381
and tolbutamide, *241, 366, 367
and tuberculosis incidence, 474
and vascular disease, *159, 300-304
widowed persons, 173
- ALANINE, *160**
intestinal absorption, 445
and phenethylbiguanide, 154, 156
- ALBINISM, heredity, 127**
- ALBUMIN**
plasma fraction, insulin antagonism,
*244
serum concentration, 10
in atherosclerosis, *402
in glomerulosclerosis, 254
specific insulin-like effects, 438-440
and tolbutamide, 286
- ALBUMINURIA**
in Charcot's disease, 193
and diabetic control, 385
in pregnancy, 17
and proliferative retinopathy, *328
and protein-bound hexose levels, 174-
178
in renal disease, 174
- ALCAPTONURIA, heredity, 127**
- ALCOHOL**
enzymatic action, and zinc, *76
and "food addiction," 377
and hypercholesterolemia, *405
and insulin antidiuresis, *404
- ALDOSTERONE, excretion after growth
hormone, *157**
- ALKALOSIS, *323, *329**
- ALLERGY, insulin, *240, *244, 390**
- ALLOXAN, diabetes. See Diabetes melli-
tus, alloxan-induced**
- AMERICAN DIABETES ASSOCIATION**
Affiliate Associations
Detection drives, 165, 249, 334, 407,
411, 414
news, 81-82, 165-166, 249-250, 336,
415, 496
annual banquet, 406-409
annual meetings
nineteenth, 78, 163, 245-247
business, 410-411
Executive Director's report, 411
President's address, 406-408
registration figures, 333
scientific sessions, 78, 246-247, 406
Treasurer's report, 410-411
twentieth, 410, 414
scientific program, 492
Banting Memorial Lecture, 337-349,
409
Banting Memorial Medals, 409
Board of State Governors, 492
Committees (1958-1959), 79-80;
(1959-1960), 493-495
on Employment, 143, 410
Executive, 410
Nominating, 412
Scientific Awards, 410
Scientific Exhibits, 235
Teaching of Diabetes in American
Medical Schools, 410
Council
Bylaw amendment, 164
elections, 333
officers and members, 78, 163, 245,
333, 406, 489
Statement on product endorsement,
248
Diabetes Week, 165, 249, 334, 407,
411, 414
essay contest, 80-81, 164, 410, 495
1958-1959 winners, 413-414
FORECAST, 407, 410, 411
Diabetics' Guide to Federal Income
Tax Deductions, 165
Reprint Series, 335
Summer Camps for Diabetic Chil-
dren, 165
Identification Card, 81, 335
International Diabetes Federation,
fourth congress, 164, 336
Journal
binders, 81, 335
editorials
Actions of Phenethylbiguanide and
Related Compounds, 154-156
Clinical Testing of Oral Hypogly-
cemic Agents, 472-473
Human Growth Hormone, 232-
233
Interrelationship of Glucose and
Lipid Metabolism, 68-69
Perinatal Infant Mortality in the
Unsuspected Diabetic, 395-
397
Significance of the Action of In-
sulin upon Muscle Mem-
brane Potential, 317-318
Tuberculous Diabetic, 473-475
Lilly award, 334, 408, 414, 495
in memoriam
Boulin, Raoul, 234
Grafe, Erich, 398
Stadie, William C., 472, 476-478
Stoney, George F., 397
necrology, 82, 166, 250, 336, 416, 472,
476, 496
new members, 81, 165, 249, 335, 414-
415, 495
news notes, 82, 166, 250, 336, 415-416,
496
obituaries. See American Diabetes As-
sociation, necrology
personals, 82, 166, 250, 336, 416, 496
postgraduate courses, 82, 164, 248,
334, 410, 412, 415-416, 489-
492
publications
binders, 81, 335
Cookbook for Diabetics, 249, 335,
411
Diabetes Guide Book for the Physi-
cian, 335
Facts about Diabetes, 81, 335
Meal Planning with Exchange Lists,
335
Reprints, 335
research fellowships, 164, 248, 334,
410, 414
scientific programs, 78, 246-247, 406
exhibits, 235
student subscription rates, 335
- AMINO ACIDS**
See also specific acids
glucocorticoid effects, 348
and glycogen synthesis, 478
in hunger and satiety, 228, 229
and hypoglycemia in sarcoma, *486-
487
and insulin, *160, *332, 478
and tolbutamide, *240
and phenethylbiguanide, 154-156
plasma concentration after carbohy-
drate, *243
in pregnancy, 15, *239, 396
protein uptake, *160, 478
and sulfonyleurea derivatives, *239,
*241
- AMINO BENZOIC ACID, *76**
- AMYL BIGUANIDE, 154, *242**
- ANDROSTERONE, excretion in preg-
nancy, 17-19**
- ANEMIA**
aplastic, and tolbutamide, *323
and chlorpropamide, 10
hemolytic, genetic basis, 288
and neuropathic joints, 192-195
normochromic normocytic, 65, 67
- ANGINA PECTORIS**
diagnosis, 174
incidence, *159
linoleate and linoleic acid effects, 181
- ANOREXIA**
and oral hypoglycemics, *485
biguanides, *242-243, 276, 277
chlorpropamide, 3
presenting complaint, 289, 290, 292
- ANTHRONE, *75**
- ANTIBIOTICS**
after Clinitest burns, *331
foot complication prevention, *325
- ANTIBODIES, insulin, *157, *240, *242,
*244, *328, *329, *481**
- ANTIDIURETIC HORMONE**
in diabetes insipidus, *487
and insulin, *404

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 251-336

March-April, 83-166
September-October, 337-416

May-June, 167-250
November-December, 417-496

SUBJECT INDEX 1959

AORTA, arteriosclerosis, 300-302, 305
and cholesterol concentration, *331
and histidine, 13
6-phosphogluconate dehydrogenase,
*324
sulfomucopolysaccharides metabolism,
*321

APPETITE
and hunger, 377
and satiety, 226-230
and obesity, 229, 377

ARABINOSE
absorption, 443
and blood sugar levels, 210
metabolism, and insulin, 35
urinary excretion, *400

ARACHIDONIC ACIDS, 184, 231, 387

ARGININE, *160

ARSENITE, *160

ARTERIES. *See* Blood vessels

ARTERIOSCLEROSIS
aortic, 13, 300-302, 305, *324, *331
calcification, 264
cerebral, 146
and cholesterol concentrations, *331
digital artery, 263
and employment, 146
glucose-6-phosphatase values, *324
and histidine, 13
and illness duration, 301-302, 304,
*480
and mucopolysaccharides metabolism,
*321
obliterans, 146
and endarteritis in extremities, 262
palpable pulses, 267
peripheral, and arterial pulse wave,
*481
spinal cord, and neuropathy, 280-283

ARTHRALGIA, 390

ARTHRITIS, rheumatoid, 94

ARYLSULFONYLUREAS, *72, *244
See also specific substances

ASPIRIN, and blood sugar, *243

ASTHMA, and diabetes, *482-483

ATELECTASIS, *323

ATHEROSCLEROSIS
and diabetes control, *405
and gamma globulin levels, *402
and gangrene, 268
and histidine, 13
peripheral, and claudication, 183
and plasma lipids, 211
after linoleate and linoleic acid, 181-
185
serum albumin concentration, *402

ATROPINE
in diabetic neuropathy, 64-67
and liver blood flow after insulin, *159

B

BANTING MEMORIAL
lecture, 337-349, 409
medals, 409

BARBITURATES
and hypoglycemic agents, *73
and pituitary function, 353

BEHAVIOR
and adaptation, 358-363, 372
feeding, and body composition, 229
cyclical changes, 226-227
and hypothalamus, 226
self-destructive, 379-382

BEHRE METHOD, modification, *70

BENEDICT'S TEST, 7

BICARBONATE, *74-75, *160

BIGUANIDES, 154, *159, *242-243,
276-277, *331
See also specific substances

BLOOD
See also Blood sugar; Plasma; Serum
amino acids. *See* Amino acids
cerebral, after convulsion, *483
in Charcot's disease, 193-195
after chlorpropamide, 3, 5
and food intake, 228-229, *238, 434-
438
glucagon-like material, assay, *326
hematocrit, 274, 277
after growth hormone, 207
hematopoiesis, 274
hemoglobin, 64, 274
in fetus of diabetic, *324
 α -ketoglutarate, 344
ketones. *See* Ketone bodies
lactate, 156, 344, 348, 434-436
loss, *238
in bullfrog, *488
in neuropathy, 64, 193-195
pepsinogen levels, 91
and gastric peptic activity, 111
peripheral, 5, 156, 274, 277, 278
and insulin resistance, *485
pH, *324
carbon dioxide inhalation, *74-75
and muscle glucose uptake, *160
and phenethylidiguanide, 156, 274, 277,
278
potassium levels, *240, *483
protein-bound hexose levels, 174-178
pyruvate, 156, 344, 348, 434-436
sodium levels, 300, *483
urea nitrogen, 64, 193, 275

BLOOD FLOW. *See* Circulation

BLOOD PRESSURE
See also Hypertension
in glomerulosclerosis, 253, 254, 299
in neuropathy, 63-67
and thyroid gland, *74
and vascular disease, 174-178, 300

BLOOD SUGAR
See also specific conditions and specific
hypoglycemic agents
and adrenal glands, 109, 200-203, 343-
344, *482
removal, 201, *320, 342-347, *402,
*403
and aging, *76, *486
after alloxanization, 8-12, 300
and heparin-induced lipemia clear-
ing factor, 212-216
after L-arabinose, 210
arterial-hepatic venous difference, *404
in bullfrog, *488
and carbohydrate, 51-55, *484
See also Carbohydrate
and carbon dioxide uptake, 344
and cardiovascular complications, *405
and cholesterol levels, *486
and cortisone, 128-131, 136, 341, 344
and cyclic or recurrent vomiting, *240
decrease without insulin, *402
and 2-deoxy-D-glucose, *325
and desoxycorticosterone, 107, 136
after dextrose, *321
and dinitrophenol, *243
and dipicolinic acid, *484
and electroencephalograms, 376
endocrine control, *241
See also specific glands
and exercise, 218
fasting, *238
discrepancies, *73
and fat stores, 229
and food intake, 227, *238, *405,
434-436
and formamidineyliminourea, *324
after fructose, 121, 122, 435
and gastric activity, 91
after glucagon, 37, 95, 111, 120-121,
*326, *405, *488
and insulin mixtures, *72, 128-131
and glucocorticoids, 22-28, 344-347
after glucose ingestion, 22-28, 121,
122, *321, 346-348, 418, 432-
437, 467, 470
and plasma insulin, 419-423
after growth hormone, 109, 208, 232,
*320
and hydrocortisone, 345
and 1-hydroxyacridine, *484
and 5-hydroxytryptamine, 393, 394
after hypophysectomy, 137, 199-201
and hypothalamic "glucoreceptors,"
228
and islet cells, 422
hypertrophy, 89
and lipocic acid, 214-216
in lipodystrophy, *327
and liver glycogen content, 154
lymph glucose equilibrium, *402
and muscle changes, 257-259
and obesity, *323, 368, 370
after pancreatectomy, 9-10, 316, *320
and picolinic acid, *484
and pteridine derivatives, *484
and remission, 189-191
after ribose infusions, 210, 455-458
self-perpetuating cycle, 422
and serum insulin-binding globulin,
429
in severe neuropathy, 64
after sucrose, *321
"suspect" group, *332
tests, 395, *401, *486

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 251-336

March-April, 83-166
September-October, 337-416

May-June, 167-250
November-December, 417-496

SUBJECT INDEX 1959

- Anthrone, *75
 Clinistix, *75, *160
 colorimetric method, *70, *479
 Folin-Wu, *70, 167, 395
 Hagedorn-Jensen, 7
 Nelson-Somogyi, 22, *70, *75, 116,
 117, 128, 167, 316, 417
 Oxford, Mass., *332
 photometric method, *75
 in threatening situation, 360-361
 and weight reduction, *323
 after D-xylose, 210
- BLOOD VESSELS**
 adenohipophysis, 355-356
 and adrenal glands, 347-348
 arteriosclerotic, *70, 146, 262-264, 267,
 302-305, *321, *480, *481-
 482
 calcification, 264
 in Charcot's disease, 194
 from carotid artery, 355
 complication development, *70, *71,
 *72, *241, *326, *405
 and adrenocorticotrophic hormone,
 347-348
 and age, *75, *159, 300-304
 and blood protein-bound hexose lev-
 els, 174-178
 cardiovascular, *405
 diagnosis, 174
 and dietary linoleic acid and lino-
 leate, 179-184
 and duration of illness, *70, *76,
 *159, 174, 178, *241, 383-
 387, *481-482
 long-term vascular syndrome, *480
 and employment, 146
 endocrine factors, 14-20, *241, 337-
 347
See also specific glands
 genetic susceptibility, *405
 incidence, *159
 mucopolysaccharide metabolism,
 *321
 in Natal Indians, *321
 peripheral, 261-273, *325, *399
 and plasma lipid, 181
 in pregnancy, 14-20, 337-349
 rice diet, *324
 and serum cholesterol, *159, 181,
 *331, 385, *402, *486
 conjunctival, *71
 and carbon dioxide inhalation, *74
 cutaneous, *238
 and glycoprotein concentration, 178
 of pancreas, *72
 protein depletion, 178, 345
 of testes, *72
 vasodilatation and liver blood flow,
 *159
- BODY**
 carbohydrate stores, and food intake,
 228, 229
 composition maintenance, 228
 density measurement, *239
 glucose pool, 107, 109, 117-121, *320
 growth, 232
 and carbutamide, 10
 after cortisone, *401
- in dwarfism, *157, *401
 and pancreatic glucagon, *320
 embryomegaly, 19, 45-50
 after growth hormone, *157, 232
 after insulin, *157, *401, 478
 and of pancreas, 88
 and pituitary function, *157, 232-
 233, *320, *401, *406
 after thyroid, *401
 nonesterified fatty acid storage, 452
 type, and phenethylguanide response,
 276
 weight. *See* Obesity; Weight
 zinc-content, *76
- BONE**
 in acidosis, mineral and water content,
 *486
 in diabetic neuropathy, 192, 195
 protein depletion, 345
- BOOK REVIEWS**
 Clinical Application of Hormone Assay,
 by John A. Loraine, 69
 Early Detection and Prevention of
 Disease, edited by John R.
 Hubbard, 318
 Insulin Crystals, by Jørgen Schlicht-
 krull, 233
 Lipids: Their Chemistry and Biochem-
 istry, by Harry J. Deuel, Jr.,
 475
 Manual of Chest Clinic Practice in
 Tropical and Subtropical
 Countries, by A. J. Benatt,
 319
 Methods of Biochemical Analysis, ed-
 ited by David Glick, 397
 Nurse and the Diabetic, by Joan B.
 Walker, 69
 Psychological Aspects of Aging, edited
 by John E. Anderson, 318
 Traitement du Diabete Infantile en
 Regime Libre, by P. Royer
 and H. Lestrade, 319
- BOULIN, Raoul, 234**
- BRAIN**
See also Hypothalamus
 adaptive reactions to stress, 358-363
 arteriosclerosis, and employment, 146
 blood potassium and sodium after con-
 vulsions, *483
 hereditary atactica polyneuritiformis,
 *402
 in hypoglycemia, *157, 376
 insulin effect, *157, 376, *483
 tumor, *485
 and carbohydrate metabolism, *488
 and cyclic or recurrent vomiting,
 *240
- BROMSULPHALEIN TEST**
 in Charcot's disease, 193
 after chlorpropamide, 1
 after phenethylguanide, 274, 277
 after tolbutamide, 285
- BUTYLAMINO BENZENESULFONYL-
 UREA. See Carbutamide**
- 1-BUTYL-3-p-TOLYLSULFONYL-
 UREA. See Tolbutamide**
- BZ-55. *See* Carbutamide
- C**
- CALCIUM**
 balance, *482
 in pituitary insufficiency, *401
 fluid space after glucose, *327
 in newborn infants, *77
 retention, and growth hormone, *157
 serum concentration, 300
- CANCER**
 adrenal cortex, *157
 duodeno-pancreatectomy, *399-400
 endometrial, *405
 pancreatic head, *399-400
 islet cells, *487
 and surgical diabetic, *239
- CAPILLARIES. See Blood vessels**
- CARBIMAZOLE, *75**
- CARBOHYDRATE**
 and blood sugar, 228, 229, 434-436
 body stores, 228, 229
 deprivation, 98
 dietary intake, 228, 229, *484
 and hyperglycemia, 98
 and hypoglycemia avoidance, *330
 and plasma, amino acids, *243
 cholesterol esters, 183
 restriction, *323
 and thyroid gland, *74
 in tube-fed rats, 51-55
 and urinary excretion, *400
 and glucagon, 98, *486
 and growth hormone, 61, *157
 and insulin, 105-110, *133, *243,
 *329, *300, 392, 423
 and ketone body formation, 133-134,
 138-139, *405
 metabolism, 61, 98, *157, *326, *486
 and adaptive reaction, 359
 and adrenal cortex, 342-348
 removal, 105-110
 and desoxycorticosterone, 106, 107
 and emetine poisoning, *71
 and environmental stress, 371
 and epinephrine, 339-340
 and glucocorticoids, 22-28
 glucose tolerance test, 22-28, 395,
 432-437
 in gout, *401
 in hemidecorticate rats, *399
 in hypercholesterolemia, *405
 and hypothalamus, *485, *488
 and nephropathy, *480
 and obesity, *323
 and oral hypoglycemic agents, 274,
 277, 370, 472
 in prediabetic stage, *405
 in pregnancy, 395
 and retinopathy, *480
 and synthetic reactions, 391
 and nonesterified fatty acids, *158,
 452-453
 and plasma amino acids, *243
 quantitative determination, *400
 serum protein-bound, in vascular com-
 plications, *402

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

SUBJECT INDEX 1959

- tolerance, 51-56, *157, 420, 472
in Charcot's disease, 194
in hyperinsulinism, *329
normal, 395
after oral glucose, 420
and weight reduction, 100, *323
- CARBON DIOXIDE**
combining power, in neuropathy, 64
expired, after D-xylose, 210
glucose synthesis, 341
and cortisone, 344
in hyperglycemia, 371
inhalation, and blood pH, *74-75
liver glycogen synthesis, 344
tension, *74-75
fetal, *324
- CARBON MONOXIDE**, *484-485
- CARBONIC ANHYDRASE**, and zinc, *76
- CARBUNCLES**, *239
- CARBUTAMIDE**
and blood glucose, 52, *240, *332, *399
and blood potassium, *240
and chlorpropamide, 5, 7, 8, 10, 12
and diguanides, *403
and growth rate, 10
insulin and growth hormone interactions, 51-56
long-term use, *488
in obesity, *399
and pancreas tomography, *485
secondary resistance, *321
and serum cholesterol, *323
side effects, *241
structural formula, 7
thyrostatic effect, *323
and tolbutamide, 8, 10, 12, *241, *403
toxicity, 10, 12
- CARCINOID SYNDROME**, 392-394
- CARCINOMA**. *See* Cancer
- CARDIOVASCULAR DISEASE**. *See* Heart, disease
- CASE REPORTS**
Addison's disease, *482
carcinoidosis, 392
chlorpropamide therapy, 4
juvenile self-destruction, 379-380
labile diabetes, 315
muscle changes, 260
remission, 189-191
- CASEIN**, *326
- CATARACTS**, 146, *159, 300, 303, *484
- CERVIX**, carcinoma, *405
- CHARCOT'S DISEASE**, 192-195
- CHILD**
brain, and hypothalamic tumor, *488
coma, 89, 290-291
diabetic. *See* Diabetes, in childhood
familial idiopathic hypoglycemia, *487
fungus, mucormycosis, *320
malformation, *77, *322, *328
mortality, neonatal, 47, *327
perinatal, *77
- CHLORIDE**
bone, in acidosis, *486
cobaltous, and alpha cell degeneration, 393
renal excretion, *72, 361
serum levels, and vascular lesions, 300
- I-(P-CHLOROBENZENESULFONYL)-3-N-PROPYLUREA**. *See* Chlorpropamide
- CHLORPROMAZINE**, *73
- CHLORPROPAMIDE**, 1-12, *159, *242, 364-367, *405
and age, 3-4, 364-370
in brittle diabetes, 5, *321, *329, 426
and carbutamide, 8, 10, 12
and hepatic glucose concentration, 5
hypoglycemia, 3, *238, 369
succinylcholine reversal, *484
metabolism, species differences, 12
and pancreas tomography, *485
and phenethylidiguamide, *479
renal excretion, 4, 12
side effects, 367, *486
structural formula, 7
and tolbutamide, 2, 8, 10, 12, *238, *239, 364-367, *479
toxicity, 1, 4, 10, 12
- CHOLANGITIS**, *328
- CHOLECYSTITIS**, *239
- CHOLESTEROL**
in arteriosclerosis, 300-305, *331
in atherosclerosis, and histidine, 13
and carbohydrate metabolism, *405
and dietary linoleic acid and linoleate, 179-188
esters, 182-184, *402
fatty acid composition, 184
feeding, and serum lipids, 300-305
liver, and glycolysis synthesis, *244
after myocardial infarction, *242
serum content, *242, *402
and age, *331, *486
and carbutamide, *323
and cortisone, *241
dietary management, *330
and electric convulsive therapy, *324
familial tendencies, 180, *330-331
and glucose, *401, *405
and growth hormone, 206
and phenethylidiguamide, 274, 277
phospholipids ratio, *402
and polysorbate 80-choline-inositol complex, *322
and Safflower oil-Sitosterol-Pyridoxine, *242
and sex, *331
and sucrose, *401
and total lipid levels, *486
and vascular changes, *159, 181, *331, 385, *402, *486
- CHOLINE**
and plasma amino acids, *243
polysorbate 80-inositol complex, *322
- CHROMATOGRAPHY**
fatty acids, 179
- insulin, in hind-limb and liver, 308-312
and mouse-convulsion assay, *322
of urine, *400
in carcinoid syndrome, 392
- CIRCULATION**
in Charcot's disease, 194
collateral, in gangrene, *239, *399
and dibenzylamine, *159
forearm, *238
and growth hormone, 205
and insulin, *159, *238
sudden failure, 390-391
liver, *159
and nonesterified fatty acid uptake, 453
plasma and lymph glucose values, *402
portal-hypophyseal system, 352, 355-356
- CITRATE**, after guanidines and Synthalin, 156
- CLAUDICATION**, intermittent, 174, 183
- CLINISTIX**
and esophageal stenosis, *331
false-positive urine tests, *75, *160
- COBALT**
and islet cells, 393
toxicity, and glucagon, 43
- COENZYME-A**, in fatty acids synthesis, 68
- COMA**
and cyclic or recurrent vomiting, *240
in diabète maigre and gras, *75, 101-102
and electrolyte disturbances in ketoacidosis, *482
in infancy, *70
and childhood, 89, 290-291
and insulin, *244
adrenocortical response, *74
and deficiency, *75, *482
and islet cell changes, *75, 89
and oral compounds, 368
peripancratic abscess precipitation, *325
and self-destructive behavior, 379-382
serum insulin-like activities, 30-35
treatment, *482
emergency, *324
and vascular complications, *71
- CONVULSION**
and brain tissue, *483
and insulin, hypoglycemia, *483
induction, *320
picrotoxin, *483
serum lipids, after electric therapy, *324
- CORONARY ARTERY**
arteriosclerosis, 280, 300-302, *324
insufficiency, 181
and employment, 146
occlusion, *238
familial tendencies, *330-331
and proliferative retinopathy, *328
- CORTISOL**. *See* Hydrocortisone

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

SUBJECT INDEX 1959

CORTISONE

- in Addison's disease, 347
- after adrenalectomy, 135-136, 139, 140
- in cholesterolemia, *241
- after Clinitest tablet, *331
- in depancreatized-hypophysectomized baboons, *241
- in dwarfism, *401
- and glucagon, 128-131, 294
- and glucose, assimilation, *238
- blood content, 128-131, 136, 341-344
- tolerance test, 190
- in hyperlipemia, 135, *241
- after hypophysectomy, 140, *241
- ketogenic effect, 134-141, *326, 346, 347
- and liver glycogen, 344
- and metabolic alkalosis, *323
- in obesity, *330
- and pancreas, *484
- islet hypertrophy, 89
- in phospholipemia, *241
- in pregnancy, 49

CREATININE, 274, 277

- in glomerulosclerosis, 253-255

CURARE, and tolbutamide, *324

CUSHING'S SYNDROME, 345

- and vascular complications, 347-348

CYANIDE, *160

CYTOCHROME, and biguanides, 155, 156

D

D-860. See Tolbutamide

DBC. See Formamidinyliminouria

DBI. See Phenethylbiguanide

DECAMETHYLENEDIGUANIDINE, *239, 393

6-DEOXY-6-FLUOROGLUCOSE, *329

- and insulin, 112-114
- structure, 112

DERMATITIS

- eczematoid, 390
- and hypoglycemic agents, *244, *405

DESOXYCORTICOSTERONE

- and carbohydrate metabolism, 106, 107
- and ketone body formation, 134-141
- and metabolic alkalosis, *323

DEXTROSE, and blood sugar, *321

DIABÈTE GRAS AND MAIGRE, *75, 101-104

DIABETES INSIPIDUS, *487

- and hypothalamic lesion, 353
- and insulin, *404

DIABETES MELLITUS

- See also specific conditions; specific hypoglycemic agents
- acute, 89
- adaptation, 359-362, 372
- addiction and "compulsive eating," 377
- and Addison's disease, 347-348, *482

and adrenal glands, 337-349

- See also Adrenal glands

adrenalin, and hyperinsulinism, *329

- age of onset, 85, 93, *158, 289-293, *481

and angiopathy, *159

- association with infection, 291, *402
- and blood insulin antagonists, 92-93
- and Glipasol, *481
- and hemochromatosis, *325-326
- and phenethylbiguanide, 274

and albuminuria, 93, 385

alloxan-induced, 7-12, 300-303, *480, *484

anterior chamber hemorrhage, *484

assay for trophic hormones, *325

bone mineral and water content, *486

in catfish, *404

and chlorpropamide, 9-12

cytology, *332

degenerative lesions, 298-305

embryomegaly, 45-50

fatty acid synthesis, 68

fetal mortality, 45-50

gastric secretion, *403

and glucagon, 124

and glucose, *479

cyclo-acetoacetate, and estrogen, *242

metabolism in muscle cells, *403

spinal cord, *160

and utilization, 116-126

and growth hormone, 205-209

lipemia clearing factor, 211-216

renal changes, *484

retention of aqueous fluoride, *488

retinopathy, *484

urinary zinc, and diphenylthiocarbazon, *480

ambulatory healthy, *244

and asthma, *482-483

asymptomatic, *486

blood sugar. See Blood sugar

brittle, 1

and chlorpropamide, 5, *321, *329, 426

carbuncles, *239

and carcinoid syndrome, 392-394

and carcinoma of endometrium, *405

and cardiovascular-renal disease, 146

and career choice, 147, *240

and Charcot joint development, 192-195

in childhood, *75, 289-293, *403, *404

brain, and hypoglycemia, 376

coma, 89, 290-291

disseminated mucormycosis, *320

dysarthria, *402

education, *402

self-injection of insulin, 374

growth, and insulin, 378

infancy, *70, *157, *158, 289-292

and islet tissue, 85, 89

management, 371, 374, *402, *404

neurologic changes, *157

oral hypoglycemics, *159, 378

and parents, 381

Refsum's syndrome, *402

response to life situation, 371

retinitis prevention, *328

summer camps, 165, 374

cholecystitis, *239

classification, 1

gras, *75, 101

and islets of Langerhans, *75

maigre, *75, 101

spontaneous, *487

tolbutamide-responsive-adult, 422

and colloidal endarteritis, 262

complications. See specific sites

and Cushing's syndrome, 347-348

diagnosis, 144-145, *323, 376-377, 395, 396, *402, *486

in older age groups, *486

"suspect" group, *332

true sugar method, 395

and dibenzylamine, *159

and dinitrophenol, *243

duration, 15, *76, *241, 300, *324, 385, *480

and arterial pulse wave, *481

and chlorpropamide, 366

and collateral circulation, *239

and glycoprotein concentration, 178

and late lesions. See specific sites

and management, *76, 196, 275, 277, *321, *324, 366, *404, 472, *481, *482

and pituitary-adrenal axis, 139

statistical investigation, 101

and threshold of vibratory perception, *487

in elderly, *238, *486

and aspirin, *243

chlorpropamide therapy, 3-4

and islet cell changes, *76

senile, *75, *76

and tolbutamide, 366, 367

and employment, *71, *74, *240, *488

by Esso Standard Oil Company, 143-147

restrictions, 146, 147-148

by state, 144

and epinephrine, *329, 339, *403

and eruptive xanthomatosis, *403

etiology, 53

family history, 25, 145, 147, *330, 373, 385, 395, *405, *482

heredity, *403-404, *405

and environment, 306

and gout, *401

and hemochromatosis, *325-326

hunger, 97-98

hypoglycemic hormone, *403

and impotence, 66, *243, 328

incidence, 100-104, 364

England, 100, 149

in industry, 144, *488

in Japan, *74

Natal Indians, 321, 322

in Netherlands, 100

in Oxford, Mass., *332

in United States, 149-152, *332, 374

See also Diabetes mellitus, statistics

and infections, 90, *241, 291, *403, *408

susceptibility, 474-475

insulogenic reserve index, 421-423

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

SUBJECT INDEX 1959

- juvenile, 92, 196, *241, 291, *324, 364, 369, 420-423, *481
and arterial complications, 92
carbohydrate tolerance, 420
carbon dioxide inhalation, *74
carbutamide, *488
and chlorpropamide, 364, 369
diet misuse, 379
duration, 92, 383-387, *483
and emotional difficulties, 381
and environment, 371-378
fatty acids uptake, 451
glycosuria, 371-372, 473
and infection, 90
and insulin, 196, 369, 417, 421-423
resistance, *321
and personality, 371-378
and phenethylidiguanide, 275
and retinopathy, *484
self-destructive behavior, 379-380
tolbutamide, *244, 364
labile, 315, 324
insulin plus biguanide, *243
metabolic response to stress, 371
latent, 191
See also Diabetes mellitus, prediabetic
lipotrophic, *401
manifestation, 375
of neuropathy, 63, *158, 394, *400
presenting complaints, *158, 289-292, *400
menopause, 101
mild, 1
and chlorpropamide, 5, *238
and fatty acids uptake, 451
and formamidinyliminourae, *324
and serum insulin binding globulin, 426
and sulfonyleureas, *329
mortality. *See* Mortality
and necrobiosis lipoidica diabetorum, *331
and osteoporosis, *482
palpable pulses, 267
and personality, 290, 371-378
prediabetes, 209, *330
and benign glycosuria, *405
and pregnancy, *77, *238, 385-386, *405
See also Pregnancy
protein-bound hexose levels, 174-178
remission, 189-191, *238
and reproduction in man, *243, *328
season and onset, 291
severe, 189-191, 195, 451
and insulin, *243, *405
phenethylidiguanide, *243, *405
sex distribution, 100, 101, 103, 151, *159, 289
skin diseases, *327, *403
stable, *240
sulfonyleurea therapy, 364
starvation, 97
statistics, 149-153
by age, 100, 151-152
of onset, 102
by area, 149
Canada mortality, 149
in countries, 149, 152
England, 100-104
and Wales, 149
by insulin use, 102, 103
investigations, 100-104
life insurance policy holders, 149
by number of children, 101
by race, 151
by sex, 100, 101, 151
diabète gras and maigre, 103
United States, 150-152
by geographic region, 150
steroid, *329
and islet cell changes, *76
"stress diuresis," 359-361
and suicide, 379, 380-382
and surgery. *See* Surgery
temporary, *322
transitory, *329
treatment, 369, 371-378, *401, 474, *485
and age, 3-4, *324, 366, 367, *403
in India, *485
seasonal, 378
secondary resistance, *321, *481
therapy selection, 1, *238, *241, *244, *326, *329, 472-473, *480, *488
See also specific substances; surgical procedures
in tropics, *321
and tuberculosis, *77, 473-475
uncontrolled, 257-260
asymptomatic hypoglycemia, *329
and ribose, 458
skeletal muscle changes, 257-259, 260
unstable, *405, *486
carbohydrate homeostasis, 374
exercise, 371
lipodystrophy, *320-321, *327
starvation, 371
and stress, 371
vibratory perception, *487
Week, 165, 249, 334, 407, 411, 414
DIARRHEA
and fat absorption, *157
insulin reaction, 390
in labile diabetes, 315
and neuropathy, 63
atropine control, 66
Charcot's disease, 192, 193
in pancreatitis, 66
side effect, of oral therapy, *242-243, 276, 277, *485
DIBENZYLIN, *159
DIET
calorie-intake, 100, 103, 364, 370
and energy expenditure, 227
glucostatic theory, 227-228
and ketonemia, *405
and phenethylidiguanide, 277
carbohydrate intake, *74, 98, 183, 228, 229, *330, *400, *484
and cholesterol levels, 183, 185, *330
and Courtice-Douglas effect, *404
in diabetes control, 100, 364, 368, *400, *402, *482
and eruptive xanthomatosis, *403
exchange technics, *482
foot complications, *325
and insulin, 100, 196, *323
dosage, 196-197
Lente, *404
reactions in children, 374
serum protein fractions, *243
misuses in young, 379
and oral therapy, *159, *244, 274, 277, 472
See also specific substances
after pancreatectomy, *400, *484
in pregnancy, *323, 396
tuberculous, 474
and emotional stress, 371, 380
essential fatty acids, meal plan and instructions, 186-188
fat-deficient, 198
fructose, and glucose tolerance, 432-437
and growth hormone, *484
and heparin-induced lipemia clearing factor, 216
and hyperglycemia, 98
hypothalamic-hyperphagic rats, 227
linoleate and linoleic acid, 179-185
after myocardial infarction, *242
and nitrogen balance, 51-55
in obesity, *321, 370
and plasma, cholesterol esters, 183
lipids, 179-185
potassium restriction, *323
rice, in vascular disease, *324
vegetable fats, 185
and weight, 51-55, 103, 227, *321, 370
DIGUANIDES, 154, *403
See also specific compounds
DIODOTYROSINE, and insulin, 308, 311-313
DINITROFLUOROBENZENE, *158
DINITROPHENOL, *160
and salicylate, *243
DIPHENYLTHIOCARBAZONE, *480
DIPHOSPHOPYRIDINE NUCLEOTIDE
and adipose tissue metabolism, 341
and fatty acid synthesis, 68, 69
and glucose-6-phosphate oxidation, 341
sorbitol reduction, *332
DIPICOLINIC ACID, *484
DIURESIS
newborn infant, *404
stress, 359-362
in transient renal insufficiency, *243
DODECAMETHYLENEDIGUANIDINE, *239
DWARFISM, *157, *320, *401
DYSARTHRIA, *402

E
EDEMA
angioneurotic, and insulin, 396
after carbon dioxide inhalation, *74-75
in Charcot's disease, 193

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

SUBJECT INDEX 1959

- in glomerulosclerosis, 253
and postnatal weight loss, *400
in pregnancy, 17, 49
- ELAIDATE**, and weight gain, 198
- ELECTROLYTES**
in diabetic mothers and fetuses, *324
after glucose infusion, *327
in ketoacidosis and/or coma, *482
and surgery in diabetes, *479
- ELECTRON MICROSCOPY**, of pancreas, 36-44
- ELECTROPHORESIS**
aqueous and plasma patterns, *401
in carcinoid, 392
glycoprotein in atherosclerosis, *402
insulin studies, 389-391
allergens, *240, 390
antibodies, *242, *244
lipoprotein analysis, *486
serum protein fractions, 385, 425
adipose tissue glucose uptake, 439
- EMBRYOMEGALY**, 15, 19, 45-50
- EMETINE**, *71
- EMPLOYMENT**, *71, *74, *488
and childhood diabetes, *240
Esso Standard Oil Company, 143-147
- ENDOCRINE GLANDS**
See also specific glands
and ketone bodies formation, 132-141, *241, 346
and phenethylbiguanide, 274, 277
in pregnancy, 14-20
- ENURESIS**, 374
presenting complaint, 289, 290, 292
- ENZYME SYSTEM**
concepts, 441
for sugar transport, 443-447
and insulin, 378
and mutant genes, 142
and islets capillaries, *72
and phenethylbiguanide, 156
and vitamins, 471
- EOSINOPENIA**
and glucocorticoids, 22, 23
time-action curve, 27
and uropepsin excretion after insulin, *483
- EPILEPSY**, and hyperinsulinism, *326
- EPINEPHRINE**
and adenohipophysis, 356, 371
anti-insulin effect, *77
in asthma and diabetes, *483
and blood sugar in bullfrog, *488
and carbohydrate metabolism, 339-340, 371
and fatty acids, 341
and glucosuria, 342
and glycogen synthesis, 340, 341
and hydrocortisone, 339
and hyperglycemia, 342
and hyperinsulinism, *329
in hyperthyroidism, *158
and lipid depletion, 341-342
and muscle cell glucose, *403
- structure, 339
and tolbutamide effects, 203
- EPITHELIUM**
ductular, *77
and diabetogenic hormones, *76
glycogen infiltration, 294
proliferation, *77, 263, 270
- ERYTHROCYTES**
after carbon dioxide inhalation, *74-75
after chlorpropamide, 1
glutathione concentration, *74
hexose transfer system, *158
intracellular, after glucose, *327
life span, after nephrectomy, *74
sedimentation rate and growth hormone, 207
- ESOPHAGUS**, cicatricial stenosis, *331
- ESSO STANDARD OIL COMPANY**, 143-147
- ESTROGEN**, 19
and glucose-cyclo-acetoacetate therapy, *242
- ETIOCHOLANOLONE**, 17-19
- EXERCISE**
in adult-onset diabetes, 368
anaerobic glycolysis, 156
and blood sugar, 218
and insulin, 218, 225
ketosis, *404, *405
lactic acid accumulation, 156
muscle adaptation, 225
and plasma amino acids, *243
tolerance, and fructose, *404-405
- EXTREMITY**
embolism and colloidal endarteritis, 262
gangrene, 267-268
of heel, *239, *399
after glucagon, *72
glucose uptake, *72
heredopathia atactica polyneuritiformis, *402
infections, *325
fungus, 193
and insulin, *72, *238, *325
metabolism, 307-313
muscle, fatty acids uptake, 450-451
neuropathy, 63-67
Charcot joint, 192-194
pain perception loss, 63, 193
roentgenographic density measurements, *239
ulcer complications, *325
vibratory perception threshold, *487
- EYES**
See also Retinitis; Retinopathy
aqueous, *401
fluoride retention, *488
cataracts, *159, *484
after cholesterol feeding, 300, 303
and employment, 146
conjunctiva, *71
and carbon dioxide inhalation, *74
examination, *159
glaucoma, *159
hemorrhage into anterior chamber, *484
- heredopathia atactica polyneuritiformis, *402
and insulin, *401
and kidney lesions, *484
macular degeneration, *159
in Refsum's syndrome, *402
in severe neuropathy, 63
vascular lesions, *72, 261
vision, *159, 370
and Charcot joints, 192

F

- FAJANS-CONN TEST**, 190
- FAMILIAL TENDENCY**, 145, 147, 373, 385, 395, *482
benign glycosuria, *405
cholesterol levels, 180, *330-331
and coma, *70
idiopathic hypoglycemia, *487
and infancy onset, *70, 291-292
- FAT**. *See* Lipids
- FATTY ACIDS**
carbon conversion to, *401
catabolism, *326
chromatography, 179
composition, 184
and epinephrine, 341
essential, 198, 231
meal plan and instructions, 186, 188
and growth hormone, 207
species difference, 232
and insulin, 68, 340-341, 453-454
metabolism, *158, 231, 451-454
nonesterified, 229, 231, 232, 450-451
and carbohydrate, *158, 452-453
and heparin-induced lipemia clearing factor, 212
and ribose infusion, 456
transport, 209
uptake, 451, 453
and phosphopyridine nucleotide, 68
and plasma lipids, 180, 182
polyunsaturated, *330
and linoleate, 387
and linoleic acid, 181, 387
release, 229, 452
and glucocorticoids, 347
serum patterns and vascular change, 385
synthesis, 452
and Coenzyme-A, 68, 69
and diphosphopyridine nucleotide, 68
and glucose metabolism, 68
in liver, 115, *244
pathways in adipose tissue, 341
restoration after fasting, 115
- FERTILITY**, and diabetes in men, *328
- FETUS**, in diabetic pregnancy, 45-50
and adrenal glands, 19
carbon dioxide tension, *324
embryomegaly, 15, 19, 45-50
loss, 46-50, *242, *323, *331, 396
intrauterine, 19, *238, 481
premature termination, *77, 395
masculinization, *327

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 251-336

March-April, 83-166
September-October, 337-416

May-June, 167-250
November-December, 417-496

SUBJECT INDEX 1959

- plasma electrolytes, *324
survival, *242, *327, *331, 395
endocrine studies, 14-21, 48-49
and maternal age, 15
and unsuspected prediabetic state, *330
and urinary corticoid excretion, 14-20
- FLUID**
cerebrospinal, hereditary ataxia polyneuritisformis, *402
electrolytes, after glucose infusion, *327
retention, *77
spinal, in Charcot's disease, 192-194
- FLUOROHYDROCORTISONE**, 27
- FOLIN-WU METHOD**, *70, 167
criteria for interpretation, 395
- FOOD**
See also Diet; Nutrition
attitude to limitation, 381
"compulsive eating," 377
hunger and satiety, 226-231
and blood constituents, 228, 229, *238, 434-436
and glucose tolerance, 432-437
and insulin requirement, 197, 374
- FORMALDEHYDE**, 15, *479
- FORMAMIDINYLIMINOUREA**, *324
- FRUCTOSE**
and blood glucose, 121-124
tolerance, 432-437
and gastric secretion, 330
and insulin, 35, 114, 121-124, *243
gastric secretion after, *330
intestinal phosphorylation and absorption, 443, 446-447
metabolism, 35
and muscle work capacity, *404
and plasma amino acids, *243
- FRUCTOSE-1, 6-DIPHOSPHATE**, 340, 343, 438
- FRUCTOSE-6-PHOSPHATE**, 340, 343, 438
- FUMARATE**, 344
- FURUNCULOSIS**, 64
- G**
- GALACTOSE**
absorption and transport, 443-445
and blood glucose level, 121-122
glycogenicity, 444
and hereditary sperocytosis, 127
and hexose phosphate esters, 443
hypoglycemic effect, 455, *487
and insulin, 35
glucose pool after, 124
and Michaelis constant, 114
release from pancreas, 455
structure, 112
urinary excretion, *400
- GANGRENE**
and atherosclerosis, 268
and collateral circulation, *239, *399
- and hypertension, 265-266
and insulin antibodies, *328
nephropathy, neuropathy, retinopathy correlation, 267-270
nonatheromatous, 261, 267, 268
- GASTRIC SECRETION**
and emotions, 363
and fructose, 330
and glucagon, 91, 111
and alloxan, *403
and glucose, *330
in Heidenhain pouch, *403
after insulin, *330
- GASTROINTESTINAL TRACT**
glucagon storage, *486
monosaccharide absorption in small intestine, 442-447
motility in hunger and appetite, 290
and oral hypoglycemic agents, 12
side effects, 10, 274, 276, 277, *324, *479
- GENES**
mutation, 142
naphthalene sensitivity, 288
- GLAUCOMA**, *159
- GLIPASOL**, *481
- GLOBIN INSULIN**, *244, 389-391
- GLOMERULOSCLEROSIS**
See also Kimmelstiel-Wilson disease
and blood pressure, 253, 254, 299
diffuse, 251-255
and nodular, relationships, 252, 254
intercapillary, 251
absence in hemochromatosis, *325
and diabetes control, 302-303
and thyroid function, *400
and retinopathy, 270-271
hemorrhage, anterior chamber, *484
proliferative, *328
- GLUCAGON**
and acidosis, 91
assay, and cortisone-pretreatment, 128-131
and blood sugar, 37, *72, 95, 111, 120-121, 128-131, *326, *405, *408
and body growth in dwarf mice, *320
and carbohydrate mobilizable stores, 98
and carbutamide, *399
and cobalt toxicity, 43
and cortisone, 128-131, 294
diabetogenic action, 94-98, 111, *399, *486
species differences, 294-297
and gastric secretion, 91, 111, *403
and glucose, *405
tolerance, 94-98
uptake, *72, *326
utilization, 120-121
and Golgi complex, 37, 42
and glycosuria, 37, 41, 43, 94-98
and hunger, 111
hyperglycemia, 37, 41, 43, *72, 94, 95, 98
and insulin, 339, *486
- mixture, 128-131
sparing action, *326
and ketone bodies, 94-98
and kidney, 38, 41, *72
-like material, assay, *326
and liver glycogen, 94, 97, 120, *486
pancreas, 111, *320
adaptation, *484
electron microscopy, 36-44
and pepsinogen level, 91
and peptic ulcer, 111
and phenethylbiguanide, 156
plasma concentration, 339
and destruction, *485
prolonged administration, 294-297
and renal function, *72
and rheumatoid arthritis, 94
secretion, *486
storage, *486
structure, 339
- GLUCOCORTICIDS**
and blood sugar, 22-28, 344-347
and chlorpropamide, 3
and fatty acid release, 347
hyperglycemic potencies, 22-28
inflammation inhibition, 22
and ketonemia, 346
metabolic reactions, 344-349
- GLUCOSAMINE**, 114
- GLUCOSE**
and acetoacetate, *76, 341
cyclo-, and estrogen, *242
and adrenal glands, 200-203, *320, 342-347, *402
removal, 105-110, 346, *402
arterial-hepatic venous difference, *404
beta cells degranulation, 470
blood levels. *See* Blood sugar
body pool, 107, 109, 124, *320
and turnover rate, 117-121
and carbohydrate utilization, *330
cerebral deficiency, and glutamic acid, *483
and cholesterol levels, *401, *405
consumption in abdominal sarcoma, *486-487
conversion to lactate, 446
and cortisone, 128-131, 136, 190, *238, 341-344, 396
and 6-deoxy-6-fluoroglucose, 112-114, *329
"dicarboxylic acid shuttle" in hyperhypoadrenalism, 343
and emetine, *71
erythrocyte, transfer system, *158, *327
excretion, in stress, 360-361
extracellular concentration, *327, *403
in fatty acid synthesis, 68
formation, species difference, 446
and fructose, 121, 122, 435
and 2,4-dinitrophenol, 446
and phlorizin, 446
and glucagon, *72, 120-121, *326, 405, *486
and glucocorticoids, 22-28, 346-348
and glucose-6-phosphatase, 340, 343
and glycogen, *71, 230, 444, 467-470

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

SUBJECT INDEX 1959

- Golgi apparatus changes after, *479
and growth hormone, 68, 109, *320, *326, *402
and hypoglycemia, 116, 167-172, *403
after hypophysectomy, 137
and insulin. *See* Insulin, and glucose
intestinal absorption and transport, *159, 442-447
and hexose phosphate esters, 443
Michaelis-Menten kinetics, 445-446
and thyroid, 444
intracellular, 112-114, 259, *327
intravenous, 124
isotope labeled, 105-110, 116-126
ketogenic potency, *76
splanchnic, *326
and lipid metabolism, 68-69
liquid, and blood-sugar, *321
and liver, 156, 467-470
blood-flow response, *159
and chlorpropamide, 5
lymph, *402
metabolism, 35, *75, 155, *329, 361
of acetate, *76
in adipose tissue, *332, 341
to carbon dioxide, 68, 154
and epinephrine, 340
in hypothermia, *157
in muscle cells, *403
and myocardial oxidative process, *238
pathways, 68, *329
and synthetic reactions, 391
osazone, 167
pancreatic perfusion and insulin secretion, 417
and phenethylbiguanide, 154, 155, 156
phosphorylation, 340, 343, 348
plasma, 339
amino acids, *243
insulin activity, 417-423
movement between aqueous and, *401
transient complete inhibition, 171
turnover, 113, 167-172
and polyhydric alcohols, *479
in pregnancy, *323, *330, *399, *404
production, 346
and growth hormone, 109
and protein uptake, *160
and pyruvate, *71
renal, 112-114
clearance, 345
threshold, *399
secretory response specificity, 121
structure, 112
tissue permeability, *403
and tolbutamide, *159, 167-172, 467-471, *482
tolerance tests, *321, *323
and carbohydrate, 22-28, 395, 432-437
and chlorpropamide, 3
-cortisone, 190, 396
in Cushing's syndrome, 348
after 2-deoxy-D-glucose, *325
and emotions, 363
and fructose, 432-437
after glucagon, 94-98
glucocorticoids, 22, 348
and growth hormone, 232
and half life, *159
in hemidecorticate rats, *399
in hunger diabetes, 98
and insulin, *159, 429
and lactic acid concentration, 434
normal, in Kimmelstiel-Wilson syndrome, *480
after oral glucose, 432-437
and prednisolone, 23, 24
and prednisone, 3
and pyruvic acid concentration, 434
in severe diabetes with remission, 189-191
after smoking, *479
and therapy duration, 429
and unsuspected prediabetic state, *330
unabsorption, 468
uptake, *72, 154, *238, *320, 348, 419-423, *482
adipose tissue, 29, 438-440
and adrenocorticotrophic hormone, 59-61, *238, *326
and anaerobiosis, 155, *160
and arsenite, *160
and bicarbonate, *160
and casein, *326
into cells, *327-328
and corticotropin, *326
and cyanide, *160
after denervation, 218-225
by hemidiaphragm, 155, 218-225
for insulin-like material assay, 29-35, 438
and insulogenic reserve index, 421
and mitochondrial oxidations, 155
by muscle, *326, *327, *479
peripheral, 154, 171
and serum phosphorus, *238
and sodium salicylate, *160
spinal cord, *160
urine excretion. *See* Glycosuria
utilization, 116-126
and adrenal cortex, 346-347
and 2-deoxy-D-glucose, *325, *329
in hunger and satiety, 228
after hypophysectomy, 107, *320
after nephrectomy, *74
species differences, 436
GLUCOSE-1-PHOSPHATE, structure, 340
GLUCOSE-6-PHOSPHATE
in fatty acids synthesis, 341
metabolism, 343
and age, *324
in glucose transport, 444
and glutathione metabolism, 288
hepatic, 340, 348
structure, 340
GLUCOSTATIC THEORY, 227-228
GLUTAMIC ACID
and insulin, *160
cerebral reactions, *483
and zinc, *76
GLUTATHIONE
erythrocytes concentration, *74
glucose-cyclo-acetoacetate and estrogen, *242
metabolism, 288
GLYCEROL
colorimetric determination, *479
and fatty acids storage, 341
hepatic, and phenethylbiguanide, 156
GLYCINE, protein uptake, *160
GLYCOGEN
in abdominal sarcoma, *486-487
and adipose tissue metabolism, 341
in adrenal cortical tissue, 343
and adrenocorticotrophic hormone, *76, 343
and chlorpropamide, 1, 5
and cortisone, 344
deposition, 154
and newborn weights, *404
tubular, 303
ductular epithelium, *76, 294
and epinephrine, 340-341
and glomerular filtration rate, 95
and glucose, *71, 230, 444, 467-470
hemidiaphragm content, 222-225
and insulin, 223, *322, 478
liver, 22, 97, 120, *322, 340-344
and adrenal gland, 342-343
after biguanides, 154, 156
and chlorpropamide, 1, 5
determination, 1, 5, *487
and glucose-6-phosphate, 340
and hypoglycin A and B, *71
storage, *487
and tolbutamide, *324, *467
muscle concentration, 154, 437
nephrosis, *331
pancreas infiltration, *325
and phenethylbiguanide, 154, 156, *239
storage, 1, *487
structure, 340
synthesis, *71, 340-344
in pigeon breast muscle, 437
and pyruvate, *71
GLYCOSURIA
adaptive reactions, 360
in adrenal cortical hyperactivity, *75
alimentory origin, 98
and aspirin, *243
and biguanides, *242, 274, 277
and carbon monoxide poisoning, *484-485
and cataracts, 300, 303
and chloride excretion, 361
and chlorpropamide, 3, 365
and corticotropin, 59-61
in Cushing's syndrome, 348
in diabetes classification, 1
and epinephrine, 342
and glomerular filtration rate after glycogen, 95
and glucagon, 37, 41, 43, 94-98
and growth hormone, 53-54, 207
and hydrocortisone, 344, 345
and hypoglycemia, *329
hypothalamic lesions, *488

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

July-August, 251-336

March-April, 83-166

September-October, 337-416

May-June, 167-250

November-December, 417-496

SUBJECT INDEX 1959

- in infancy, *157
intermittent, *486
in carcinoidosis, 392
and oral agents, 473
See also specific substances
after pancreatotomy, *400
in prediabetic state, *330, *405
steroid diabetes, *329
and threatening situation, 359
and tolbutamide, *159
in young diabetic, 371-372, 473
- GOLGI COMPLEX**
and glucagon, 37, 42
and insulin, *479
- GONADOTROPHIN**
assay, after hypophysectomy, *325
chorionic, excretion and fetal survival, 19
pituitary, hypothalamic control, 353
- GOUT**
and carbohydrate metabolism, *401
after linoleate and linoleic acid, 181
- GRAFE, ERICH**, 398
- GROWTH HORMONE**
after adrenalectomy, 109-110, 140, *320
and adrenocorticotropin, 59-61, *76
anti-insulin effect, 109
and body growth, *157, 232-233
and carbohydrate metabolism, 109-110, *320
diabetogenic effects, 51-55, 57-61, 135
and dwarfism, *157, *401
and glucose, 68
body pool, 109, *320, *326
and glycosuria, 53-54, 207
and hydrocortisone, 59-61, *76
after hypophysectomy, 109, 140, *320
assay, *325
and insulin, 57-61, *157, 232
carbutamide interactions, 51-56
dosage, 109
sparing, *826
and islet hypertrophy, 89
in ketone body formation, 208, 232
and lipid, 232, *320
transport, 205-210
metabolic effects, 232-233
human and monkey, *157
nitrogen storage, 61
and nonesterified fatty acids, 207-209
after pancreatotomy, 58, 61
protein-sparing effect, 208
secretion, 86
in adult life, 233
hypothalamus control, 353
- GUANIDINES**, 155
and Synthalin, 156
See also specific substances
- H**
- HAGEDORN-JENSEN**, test, 7
- HEART**
See also Myocardium
arrhythmias, and hypokalemia, *329
congestive failure, *238
energy utilization, *238
muscle, and insulin, *326
vascular changes, 385
- HEART DISEASE**
and age, *159
atherosclerotic, incidence, *159
coronary, *331
and linoleate, and linoleic acid, 181
and employment, 146
and flushes, 394
and renal disease, 146
- HEMAGGLUTINATION**, *328
- HEMOCHROMATOSIS**, *241, *325-326
genetic, and siderosis, 306
insulin and liver extract, *328
- HEMORRHAGE**
eye, anterior chamber, *484
intestinal, 10
and intrauterine death, *238
and vascular state, 385
- HEPARIN**, and lipemia, clearing factor, 211-216
- HEPATECTOMY**, 348
- HEPATITIS**, *481
- HEREDITY**
See also Familial tendency
albinism, 127
alcaptonuria, 127
in anemia, 288
of diabetes, 88
in Chinese hamsters, *403-404
and environmental interactions, 306
and vascular disease, *405
and fetal size, 49
and glucocorticoids effects, 25
of sperocytosis, and galactosemia, 127
- HEREDOPATHIA ATACTICA POLY-NEURITIFORMIS**, *402
- HEXOSES**, *242
fat content after linolenate, 387
Michaelis constant, 114
monophosphate shunt for lipid synthesis, *244
phosphorylation theory, 443-445
serum protein-bound, 174-178, *402
transfer system in erythrocytes, *158
- HEXOSE-6-PHOSPHATE**, 443
- HISTIDINE**, 13
- HORMONES**
See also specific substances
adrenocortical, 132-141, 339-342
in diabetic pregnancy, 15-16
diabetogenic and pancreas, *76, *484
female sex, *327, *323
pituitary, secretion, 352-357
somatotrophic, of baboon, *241
- HUNGER**
and body composition, 229
and carbohydrate supply, 228
and glucagon, 111
and obesity, 377
and operant conditioning, 226
and satiety, 226-230
cyclical changes, 227
- HYALINE MEMBRANE DISEASE**, *320, *323
- HYALINOSIS**, *77, 83, *240
- HYDANTOINS**, *332
- HYDRAMNIOS**, *242, *323, *331, 396
- HYDRATION**, *482
and Courtice-Douglas effect, *404
- HYDROCORTISONE**
and blood sugar, 345
and central nervous system, 388
delayed hyperglycemic effect, 23-24
eosinopenic time-action curve, 27
and epinephrine, 339
and glycosuria, 344, 345
and growth hormone, 59-61, *76
in hypoglycemic management, *403
and infection, *77
and liver enzymes, 343
and lymph glucose, *402
plasma concentration, *330, 339
and protein catabolism, 345
structure, 339
- HYDROXYACRIDINE**, *484
- 17-HYDROXYCORTICOSTEROIDS**
adrenal output, *401
and obesity, *330
plasma concentration, 348
and glucose tolerance, *74
urinary excretion, after insulin, *74, *483
after phenethyldiguanide, 274, 277
- 17-HYDROXY-11-DESOXYCORTICOSTERONE**, 17-19
- 5-HYDROXYINDOLEACETIC ACID**, 392
- 8-HYDROXYQUINOLINE**, *484
- 5-HYDROXYTRYPTAMINE**, 393
- HYPERBILIRUBINEMIA**, *77
- HYPERGLYCEMIA**
blood pepsinogen levels, 91
and carbohydrate ingestion, 55, 98
and carbon dioxide concentration, 371
catfish, *404
and cerebral damage, *485, *488
and chlorpropamide, 1, 3, 364-367
in Cushing's syndrome, 348
and cyclic or recurrent vomiting, *240
in depancreatized-hypophysectomized baboons, *241
in diabetes classification, 1
and epinephrine, 342
after glucagon, 37, 41, 43, *72, 94, 95, 98
glucocorticoid potency, 1, 22-28
glycogen infiltration, *325
and growth hormone, 53-55, 207
and 8-hydroxyquinoline derivatives, *484
hypothalamic lesions, *488
after insulin toxicity, *328-329

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

and insulogenic reserve depletion, 422
and islet cell changes, *75, *325
and muscle cell glucose, *403
neurologic disorders, *157
and oral hypoglycemic agents, 473
See also specific substances
after pancreatectomy, *400
and phenethylidiguanide, 274, 277
and prednisolone, 23, 24
and tolbutamide, 364-367, 422

HYPERINSULINISM
and adrenal-pituitary system, *329
diabetogenic effect, *329
and epilepsy, *326
and hypoglycemia, *326, *327
classification, *487
intrauterine fetal, 49
after insulinomas removal, *326

HYPERLIPEMIA, *405
See also Lipids
and cortisone, *214
and ketosis, 134-141, 257, *405
after pancreatectomy, *320
and xanthomatous nodules, *327

HYPERTENSION
See also Blood pressure
and arterial pulse wave, *481
diagnosis, 174
and employment, 146
and Kimmelstiel-Wilson lesions, *75
and proliferative retinopathy, *328
and protein-bound hexose levels, 174-178
and senile diabetes, *75
and vascular disease, *159, 174, 175, 261, 264, 267
gangrene, 265-266

HYPERTHYROIDISM
and epinephrine excretion, *158
nonesterified fatty acid uptake, 453

HYPOGLYCEMIA
See also Blood sugar; specific hypoglycemic agents
in abdominal sarcoma, *486-487
and adrenal gland, 140, *241, 344, 346, *401, *482, *487
cortical carcinoma, *157
asymptomatic, 329-330, *402
cerebral responses, *157, 376
classification, *487
complications of gastric surgery, *401
dermatitis, *405
and emotional stress, 380
and epinephrine excretion, *158
familial idiopathic, *487
fatal, 368
and forearm blood flow, *238
functional, *487
and serum insulin binding globulin, 426
and glucose, 116, 167-172, *403
and glycosuria, *329
and Golgi apparatus, 39, 42, *479
and high-carbohydrate diet, 55, *330
and hyperinsulinism, *326, *329, *487
and hypoglycin, A and B, *71

and insulin substitutes. See specific substances
ketone body formation, 140, 346
and liver blood flow, *159
management, 100, *329-330, 371-372, 379, *403
succinylcholine reversal, *484
neurologic manifestation, *401
nitrogen excretion, 344
pregnancy, normal, *399
presenting complaint, 289, 290, 292, 422
after saccharin, 405
tobacco, *479
and veronal, *73

HYPOGLYCIN A and B, *71

HYPOKALEMIA
and steroid diabetes, *329
in transient renal insufficiency, *243

HYPOPARATHYROIDISM, 181

HYPOPHYSECTOMY
and adrenalectomy, 106-110, 200
and tolbutamide, 199-204
and adrenocorticotrophin, 137
and blood ketone bodies, 132-141, *241
and carbohydrate metabolism, 105-110
and cortisone, 137, 140
in depancreatized baboons, *241
and plasma albumin, *244
and diabetes complications, *72
epinephrine secretion after, 203
glucose utilization, 107, *320
gonadotrophin assay after, *325
and growth, 353
hormones, 135, *320
mammary gland development, *479
and insulin, 105-110, 200-202, 232
pancreas content, 204
for nephropathy, *483
and pancreatectomy, 137
baboons, *241
and phenethylidiguanide, 275
for retinopathy, *483
and tolbutamide, 199-201
for vascular complications, *241
weight, and forced feeding, *479

HYPOPHYSIS, anterior. See Adenohypophysis

HYPOTENSION, in neuropathy, 63-67

HYPOTHALAMUS
and adenohypophysis, 352-357
circulation, 352
and energy balance, 226
and food intake, 226, 228
lesions, 353
and hyperglycemia, *488
and thyroid function, 353
-neurohypophyseal system in diabetes insipidus, *487
obesity, *479
-pituitary complex, 352
and gonadotrophin release, 353
tumor and carbohydrate metabolism, *485, *488

HYPOTHERMIA, *157

I

ILETIN. See Insulin

IMPOTENCE, 66, *243, *328

INDUSTRY. See Employment

INFANT
atelectasis, *323
butanol iodine content, *329
calcium and phosphate blood levels, *77
diabetes onset, *157, *158, 289-291
and coma, *70
presenting complaints, 289
sex distribution, 289
symptoms, 289
See also Diabetes, childhood
hyaline membrane disease, *320, *323
hyperirritability, *77
hyperphosphatemia, *77
and maternal diabetes, 19, *73, *77, *322, *324, *328
care as premature, *323, *327, 395
prophylactic oral glucose, *327
See also Pregnancy
mortality, *73, *77, *320, *323
and paternal diabetes, *328
postnatal weight loss, *400, *404
sex ratio, *328

INFECTION
and aging, *76
in Charcot's disease, 193
and chlorpropamide, *242
and diabetes, *403, 474-475
association with onset, 291, *402
duration, *76, *241
management, *403
fungus, 193
mucormycosis, *320
unstable, 371
after growth hormone, *77
after hydrocortisone, *77
and insulin, *244
requirement, 196, *242
and ketosis, 372
and metabolism, *71, 90
and susceptibility, 474-475
monilia, *327
mucormycosis, *320
Natal Indians, *321
pyogenic, *327
and tolbutamide, 366, 368
tuberculous. See Tuberculosis

INSULIN
action, *244, *330
age, and age of onset, 101, 103
diminished returns, *330
pigeon breast muscle, 437
site, and reserve depletion, 422
and adipose tissue, 30-35, *321, *332, 341, *401, 478
and adrenal glands, *74, *158, *330, 348, *483
in nitrogen loss, 57-61
after removal, 105-110, 200, 342
and adrenocorticotrophic hormone, *74, *240, *322, *326, 430
and alpha keto acid metabolism, *76

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

SUBJECT INDEX 1959

- and amino acids, *160, *239, *243, 478
antagonists. *See* Insulin, resistance
antidiuresis, *404
and arabinose distribution, 35
and arylsulfonylureas, *72
assay, 33, *71, *327, *330, *482
chromatography and mouse assay
methods, *322
fluorescent antibody method, *403
and skin reactions, 390
in vitro methods, 218-225, 459-465
and biguanides, 154, *242, *243, *331, *403
See also specific compounds
binding, *244, *329, *481
hemidiaphragms, 221-223, *322
by leukocytes, *76
rabbit antihuman gamma globulin, *329
serum globulin, *242, 425, 426, 429-431
and blood flow, *159, *238
sudden failure, 390-391
and body growth, *157, *401, 478
and carbohydrates, 105-110, *133, *243, *329, *330, 392, 423
and carbutamide, 51-56, *488
and chlorpropamide, 4, 11, *73, *242, 365-367, *486
and coma, *74, *75, *244, *482
concentration after death, *70, *71
convulsion induction, *320
crystalline, *244
and 6-deoxy-6-fluoroglucose, 112-114
in diabetes control, 11, *71, *75, 106, *238, *339, *240, *243, 390, 426, *482
brain responses, *157, 376, *483
in childhood, 373-374, 376, *404
self-injection, 374
and classification, 1, *487
and diet, 100, 196-197, *243, *323, 374, *404
emergency treatment, 369
and fetal salvage, 395
requirements. *See* Insulin, requirements
and retinopathy, *328, *480
severe, *243, *405
therapeutic aims, 100
in tropics, *321
tuberculous, 474
dosage, 109, 196-197, *330, *404, 429
self-destructive behavior, 379
and sulfonylurea, *241
and urinary corticoid excretion, 19
electrophoretic fractions, *242, *244, 389-391, *401
allergens, *240, 390
in epididymal tissue, 33, *330, *332, 461-462
and epinephrine excretion, *158
and eruptive xanthomatosis, *403
and exercise, 218
extracellular concentration, 462-464
and fatty acids, 68, 340-341
nonesterified, 451-454, 457
and forearm blood flow, *238
and formamidinyliminourae, *324
and fructose, 35, 114, *243
and galactose, 35, 114, 124, 455
and gangrene, 267
gastric secretion after, *330
Globin, *244, 389-391
and glucagon, 339, *486
mixture, 128-131
sparing action, *326
and glucose, 116-126, *159, *238, *240, *330, 390, *400, *401, 455
body pool, 107, 109, 118, 124
and cyanide, *160
after epinephrine, *77
in eviscerated-nephrectomized animals, 112-114
and Golgi apparatus, *479
intracellular transfer, 112, *403
lipogenesis from acetate or pyruvate, *332
metabolism, 35, *332, 457
after norepinephrine, *77
peripheral infusion, 417-423
pituitary role, 200-201
and protein, amino acid uptake, *160
uptake, 30-35, 155, *320, *326, *327, 419, 420-423
after denervation, 218-225
and glycogen, 223, *322, 478
and growth hormone, 51-55, 57-61, 109, 157, 232, *326
and guanidine derivatives, 154, *239
See also specific compounds
and heparin-induced lipemia clearing factor, 213, 215-216
in hyperthyroidism, *158
after hypophysectomy, 105-110, 200-202, 232
immunologic methods, *329, *482
and infection, 196, *242, *244
intramuscular injections, *327
and isoleucine, *160
isotope labeled, *77, *238, 307-314, 425, 459-465
and ketone bodies, 73, 133-137, *241, *482
in Japan, *74
and lactate concentration, *240
Lente, *244, 389-391, *404
lethal doses, protection, *322
-like activity, 438, *481, *485
lipodystrophy, *321, *327
and liver, 105-106, 107, 133, *159, 172, 308, 311, *322, 478
and mammary gland development, *479
metabolism, *326, *332
inhibitor, *332
perfusion technic, 307-314
in vitro assay, 459-465
murder, *70, *71
and muscle, *403, *479
membrane potential, 317-318
ventricular, *326
and nephropathy, *480
and nitrogen storage, 61
NPH, *244, *327, 389
and pancreatectomy, 58, 133, 286-287, 315-316, *320, *400, *486
parenteral, 221-223
and pentose metabolism, 6, 35, 457
and peptic ulcer formation, 449
and phenethyldiguanide, 276
in plasma, 123-126, 417-423
and aqueous, *401
inhibitors, 385
and muscle, *403
retention, 429
turnover, 167-172
and potassium levels, *160, *240
movement, and ion concentration, 317
in pregnancy, 15, *74, *239, 396
predelivery, *327
pretreatment, and oral medication trial, *332
protein complex, time factor, 430
and pyruvate concentration, *240
reactions, *159, 219
allergic, *240, *244, 388-391
angioneurotic edema, 390
arthralgia, 390
in children, 374
cholangitis, *328
dyspnea, 390
and emotional stress, 372, 380
hemagglutination, *328
rate, and administration route, 171
recrystallized, 389-391
requirements, 1, 15, 101, 103, *242, 285-287, *329, 385, 429-431, *486
and age, 196
in Charcot's disease, 194
and diet. *See* Diet
and employment, 145, 147
and ketoacidosis and/or coma, *482
and oral agents, 154, *159, *243, 276, 277, *324, *331, 365-367, *403, 472, *488
See also specific compounds
overweight women, 104
and prednisolone, 428, 430
and retinopathy, *401
and senile diabetes, *75
reserve, 423
depletion, 422
resistance, 92, 93, *157, *321, *322, 430, *481, *485
antagonist detection, *244, *322
antibodies, *157, *240, *242, *244, *328, *481
nonprecipitating, *329
and arterial complications, 92
and fatty acid uptakes, 452
idiopathic, *240
in KL strains, *320
late, in pregnancy, *399
in plasma, *244, 385
and remission, *244
secondary, *321
steroid diabetes, *329
and type of insulin, *244
secretion, *329, 417
and glucocorticoid, 346
Semilente, *244
sensitivity, 128-131, *159, 220, 371-372, 451, 453, *485
and Addison's disease, 342, *482
diabète gras and maigre, 102

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

July-August, 251-336

March-April, 83-166

September-October, 337-416

May-June, 167-250

November-December, 417-496

SUBJECT INDEX 1959

in hemidecorticate rats, *399
in hypercholesterolemia, *405
in hyperinsulinism, *326
Natal Indians, *321, *322
serum fractions, *238, *243, *329, *484
and splanchnic ketone production, *326
and stimulation of pituitary-adrenal system, *330
structure, 339
species differences, 424
subshock therapy, *241-242
and sulfonylureas, *329
See also specific substances
and tolbutamide, *77, *158, *159, 167-172, 199-203, *239, *240, *241, 285-287, 311, 315, *400, 421-423, *482, *488
tolerance tests, *326, 371-372
in obesity, *330
and ovariectomy, *70
and total lipids, 133-137
and tuberculosis, *77
and veronal, *73
withdrawal, 417, 472-473
zinc suspensions, 389-391

INSULINASE, and liver glucose, *326

INSULINOMA, *326

INTERNATIONAL DIABETES FEDERATION, *71, 164, 336

IODINE

butanol-extractable, *329
protein bound, and phenethyldiguanide, 274, 277
radiolabeled, 308-311
renal clearance, *400

IPTD. *See* *p*-Aminobenzolsulfonamidisopropylthiodiazol

ISOAMYLBIGUANIDE, 154, *242

ISOCITRIC ACID, *77, *244

ISOLEUCINE, *160

ISOPROPYL, *241, *485

J

JAPAN, ketone body study, *74

JOINTS, Charcot, 192-195

K

KETOACIDOSIS

See also Acidosis, diabetic; Ketosis
and coma, 368, *482
fetal survival rate, *331
and insulin, *241, *482
after pancreatectomy, *400
and phenethyldiguanide, 276, 277
remission, 191
and tolbutamide, *241

α -KETOGLUTARATE, 344
after fructose, *76

KETONE BODIES

See also Ketoacidosis; Ketonuria
and acetate, *76
urinary excretion, 100

and adrenal glands, 109, 132, 140, 346

after adrenocorticotrophic hormone, 134, 136-141

in baboons, *241

blood content, *74, *76, 95, 109, *402, *405, 473

endocrine control, 132-141, *241, 346

and caloric intake, *405

and cortisone, 134-141, *326, 346, 347

determination method, *70

and emotional stress, 361, 371

and environmental temperature, *405

and fluid intake, *405

and glucagon, 94-98

and glucose, *76, *326

after glycogen, 95

and growth hormone, 208, 232

after hypophysectomy, 132-141, *241

and insulin, *73, *74, 133-137, *241, *482

and lipid concentration, 134-141, 257, *405

and oral agents, 364-367, 473

See also specific compounds
after pancreatectomy, 133, 134, 138-141, *241, 320, 346

and pyruvate, *76

splanchnic production, *326

suggested normal levels, *403

variation in healthy young men, *402

KETONURIA

and aging, *76

and caloric intake, *405

and chlorpropamide, 365

and diabetes duration, *76

and environmental temperature, *405

and fluid intake, *405

after insulin, 133

neurologic disorders, *157

after pancreatectomy, 132-141

and plasma fatty acids, 458

and ribose infusion, 456, 457, 458

seasonal changes, *74, 134, *402

KETOSIS

and Addison's disease, *482

Courtice-Douglas effect, *404

and emotional conflicts, 371, 372

exercise, *404

and glucocorticoid, 346

hepatic carbohydrate content, *320

and infection, 372

and insulin, *77

type for, *244

and islet cell changes, *75

and muscle lipid concentration, 257

nutritional, *405

after pancreatectomy, *320

and body fat stores, 139

and phenethyldiguanide, 276, 277

and skeletal muscle changes, 257

and sulfonylureas, *74

and tolbutamide, *244

17-KETOSTEROID, urinary

after insulin, *483

coma, *74

and phenethyldiguanide, 274, 277
in pregnancy, 17

KIDNEY

See also specific conditions

complications, *331, *486

albuminuria, 174

and anterior chamber hemorrhage, *484

biopsy, 251

diagnosis, 38, 41, 174

employment, 146-148

vascular, *72, 261, 280

and dietary fatty acids, 185

and dodecamethylenediguanidine, *239

electron microscopy, 38-41

fat deposition, 41, 133, 139

after pancreatectomy, *320

and glucagon, 38, 41, *72

and glucose, 112-114

clearance, and hydrocortisone, 345

and insulin, 133, *486

and phenethyldiguanide, 154, *239, 274

phospholipid contents, 133

and tolbutamide, *482

transient insufficiency, *243

KIMMELSTIEL-WILSON SYNDROME

See also Nephropathy

and alcoholic portal cirrhosis, *75

diet, and insulin requirement, 197

and nephrotic syndrome, 251-255

nomenclature, 251, 255

nondiabetic, *75

and normal glucose tolerance, *480

L

LACTIC ACID

and acetate metabolism, *76

in alloxan diabetes, 48

blood concentration, 155, 156, 434-436

after biguanides, 155

and Synthalin, 156

after glucocorticoid, 344, 348

and insulin, *240

enzymatic action, and zinc, *76

and epinephrine, 341

and glucose, 155

metabolism, species difference, 446

tolerance, 434-436

and glycogen glycolysis, 340, 341

and intestinal mucosa, 446

ketogenic potency, *76

and phenethyldiguanide, 156

LEUKOCYTES

after chlorpropamide, 1

and phenethyldiguanide, 274, 277

and sulfonylureas, *244

LIGNOCAINE, *238

LINOLEAIDATE, 198

LINOLEATE, 387

dietary, and plasma lipids, 179-188

LINOLEIC ACID, *158

and deficiency symptoms, 198

dietary, and plasma lipids, 179-185, 186-188

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

July-August, 251-336

March-April, 83-166

September-October, 337-416

May-June, 167-250

November-December, 417-496

SUBJECT INDEX 1959

- metabolism, 231
in peripheral vascular disease, 184
and weight, 198
- LINOLENATE**, 231, 387
- LIPID**
absorption, 64-67
and diarrhea, 65, *157
acinar cells, and glucagon, 37-44
and beta-lipoproteins levels, *486
blood, 211-216, *320
and adrenal and pituitary hormones, 134-141
and ethyl oleate, 179
concentration in baboons, *241
dietary intake, 180, 182, 228, *405
after myocardial infarction, *242
femoris muscle, 257
fetal concentration, 48
newborn weight changes, *404
of glomeruli, 302-303
and growth hormone, 205-210, 232, *320
after hypophysectomy, 137, *214
and insulin, 133-141, *321, *327, 341, 478
and ketosis, 134-141, 257, *405
and liver, 139, 208, 244
metabolism, *320, 341, 378
and glucocorticoids, 345
and glucose, 68-69
and myocardial oxidative process, *238
pathways, *244, 457
and skin lesions, *327
and stress, 359, 361
and synthetic reactions, 391
and necrobiosis, *327
after pancreatectomy, 134-141, *241, *320
in pheochromocytoma, 341-342
plasma, 181
and linoleic acid and linoleate, 179-185
and prolactin, 137
roentgenographic measurements, *239
serum, 385, *402, 486
and cholesterol feeding, 300-305
heparin-induced clearing factor, 211-216
in severe neuropathy, 64-67
storage, 139, 228, *320
sites, 341-342
and thyroid stimulating hormone, 137
tissue concentration, 37-44, 134-141
adipose, 345-346, *401
epididymal, *332
transport, 205-210
vascular disease, 261-273, 385
and atherosclerosis, 211-216, *402
- LIPOCAIC ACID**, 214-216
- LIPODYSTROPHY**, insulin, *321, *327
- LIPONEUROSTATIC THEORY**, 228
- LIPOPROTEIN**
anti-insulin activity, *484
in atherosclerosis, *402
and cholesterol levels, *402, *486
electrophoresis, *486
and growth hormone, 207
serum patterns, 209, 385
and electric convulsive therapy, *324
transport in prediabetic state, 209
- LIPORMONE**. *See* Lipocaic acid
- LIPOSTATIC THEORY**, 228
- LIVER**
and amino acids, *243
"trapping," 348
blood flow, and insulin, *159
carbohydrate content, 139
and ketosis, *320
carbon dioxide fixation, 348
cells, 10, 41, 44
after dodecamethylenediguanidine, *239
and chlorpropamide, 3, 10
cholesterolgenesis and glycolysis, *244
cirrhosis, *328
postalcoholic zinc content, *75
and corticosteroids, *322
in diabetes, *71
classification, *487
and duration, *480
senile, *76
synthetic reactions, 391
electron microscopy, 38, 41
enzyme system, 343, *486
extract, hemagglutination reaction, *328
fatty, 133
excess deposition, 139
and growth hormone, *320
nonphospholipid, 139
after pancreatectomy, *320
and plasma amino acids, *243
fatty acids, *244
nonesterified, 452
synthesis after fasting, 115
fructose-1, 6-diphosphatase activity, 340
function, 3, *71, *243, 274, 277-278, 284, *401
and Glipisol, *481
and glucagon, 38, 41, 44, 97, 111, 120, 344, *486
-like material assay, *326
and glucocorticoids, 22, 343, 348
and glucose, 467
isotope-labeled, 121
plasma concentration, 172
production, 105-107, 133, 172, *326, 340, 343-344
glucose-6-phosphatase, 340
glycerol, and phenethylbiguanide, 156
glycogen, 1, 5, 22, *71, 97, 120, 156, *239, *324, 340-344, 367, 467, 470, *487
and hydrocortisone, 343, 344
hypoglycemic agents, *479, *481
See also specific substances
and insulin, 105-106, 107, 133, *159, 172, *322, 478
metabolism, 308, 311, 312
in Kimmelstiel-Wilson lesions, *75
lipid content, 139, 208, *244
metabolism, 156
and synthetic reactions, 391
parenchymal involvement, *481
perfusion, iodoinsulin studies, 307-313
and phenethylbiguanide, 154, 156, *239, 274, 277
phosphofructokinase activity, 340
phospholipid contents, 133
protein release, 348
and tolbutamide, 172, 284, *324, 467
and trypsin, *326
vasodilator substance liberation, *159
- LUNG**
See also Tuberculosis
adaptive response, 359
and diabetes duration, *480
- LYMPH**, glucose, *402
- ## M
- MALABSORPTION**, 64-67
- MALIGNANCY**. *See* Cancer
- MALNUTRITION**. *See* Nutrition
- MAMMARY GLAND**
development, *479
fat synthesis, and insulin, 478
lactation, in alloxan diabetes, 48
- MANNITOL**, *479
- MANNOSE**, 114, 443
- MENINGITIS**, *70, *325
- MESOXALIC ACID**, *74
- METAHEXAMIDE**, *332
- METHIONINE SULPHOXIDE**, *160
- METHYLARACHIDONATE**, 387
- MÖNCKEBERG SCLEROSIS**, 268, 271
- MONICHOHL**. *See* Polysorbate 80-choline-inositol complex
- MONOSACCHARIDE**, intestinal absorption, 442-447
- MORTALITY**
See also Diabetes mellitus, statistics
and diabetes, 147, 149-153
comparability ratio, 153
fetal, 19, *238, 395
and cortisone, 49
and embryomegaly, 45-50
intrauterine, 19, *238
maternal factors, 15, *322, *330, 396-397
and glucagon, 41
in industry, 147
newborn, *328, *330, 396-397
hyaline membrane disease, *320, *323
and proliferative retinopathy, *328
and self-destructive behavior, 381
sex incidence, 152, 173
- MUCOPOLYSACCHARIDES**
deposition, *76
metabolism, *321
- MUCORMYCOSIS**, *320

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

July-August, 251-336

March-April, 83-166

September-October, 337-416

May-June, 167-250

November-December, 417-496

- MUSCLE**
 acetoacetate uptake, *479
 adaptation during exercise, 225
 amino acid uptake, 478
 cells, 6, *160
 and 6-deoxy-6-fluoroglucose, 114
 permeability, 114, 224
 and plasma glucose, *403
 forearm, 451, 452
 isotope clearance, *238
 and glucose, 6, *160, 223, 224, 478
 and casein, *326
 isotope-labeled, 121
 uptake, *479
 and phenethylbiguanide, 156
 glycogen synthesis, 478
 after adrenalectomy, 342-343
 and epinephrine, 340-341
 and insulin, 6, *160, 223, 317-318,
 *326, *403, 478, *479
 after ketoacidosis, 257
 membranes, 6
 potential, 317-318, *326
 metabolism, 391
 and nonesterified fatty acids, 450-
 454
 and sulfonylurea compounds, *241
 nitrogen content, 257, 258
 paralysis, *160
 potassium movement into, 317-318
 protein depletion in Cushing's syn-
 drome, 345
 septal vessels, 265, 266
 in uncontrolled diabetes, 257-259
 ventricular, *326
 work capacity, 224
 and fructose, 404-405
 humoral factor, 224
- MYOCARDIUM**
 infarction, and cholesterol levels, *242,
 *331
 oxidative process, *238
- MYRISTIC ACID, 184**
- N**
- NADISAN. See Carbutamide**
NAPHTHALENE, sensitivity, 288
NATAL INDIANS, diabetes, *321, *322
**NECROBIOSIS LIPOIDICA DIABETI-
 CORUM**, *327, *331
NELSON-SOMOGLYI TESTS, 22, *70,
 *75, 116, 117, 128, 167, 316,
 395, 417
NEPHRECTOMY, *74
NEPHROPATHY
See also Kidney
 diabetic control and status, 385
 diet and insulin requirement, 197
 and gangrene of lower extremity, 267,
 268, 270
 and glomerulosclerosis, 251-255
 and glucose tolerance tests, *480
 and insulin, 268, *480, *486
 antagonist, 93
 and liver extract, *328
 malignant, *328
 management, 268, *331
 nomenclature, 255
 and thyroid function, *400
- NETHERLANDS**, diabetes, 100
NEURONS, in diabetes insipidus, *487
NEUROPATHY
 and bone destruction, 192
 and carbohydrate metabolism, *488
 case report, 280
 Charcot's disease, 192-195
 and diarrhea, 64-67
 and duration of illness, 63
 and gangrene of lower extremity, 270
 lesion sites, autopsy findings, 280-283
 manifestations, 63-67, *157, *400
 hand numbness, 394
 presenting complaint, *158, *400
 review of literature, 279-280
 and tolbutamide, *322
 and vascular lesions, 266, 281
 vibratory perception threshold, *487
- NICOTINAMIDE, *74**
NITROFURANTOIN, 288
NITROGEN
 amino, late in pregnancy, *399
 balances, *327
 and adrenal glands, 51-61, 343-346,
 *482
 in pituitary insufficiency, *401
 steroid diabetes, *329
 cellular fluid space, *327
 diaphragm, after phrenicotomy, 221
 excretion, 58-61, 343-346, *482
 and glucose, *327, 345
 and insulin, 61, 133
 carbutamide combination, 53-54
 isotope labeled, 256-258
 loss, 59-61
 nonprotein, 300
 retention, 133
 growth hormone, 53-54, 61, *157
 and high-carbohydrate diet, 55
 storage, 58-61, 345
- NOREPINEPHRINE**
 and glucose utilization, *77
 in hyperthyroidism, 158
 and lipid depletion, 341-342
- NUTRITION**
See also Diet
 in childhood diabetes, *402
 and ketosis, *405
 requirements, and obesity treatment,
 *479
- O**
- OBESITY**
 adrenocortical function, *330
 and age, 197
 of diabetes onset, 100-104
 and appetite, 229, 377
 and blood sugar, *323, 368, 370
 caloric intake control, *321, 364, 368,
 370
 and carbohydrate metabolism, *323
 and carbutamide, *399
 and chlorpropamide, 364
 and "compulsive eating," 377
 emotional problems, 375, *405, *479
 and employment, 146-148
 and family, 375, *405
 and fat stores, 229
 and hunger, 377
 hypothalamic, 229, *479
 -hyperphagic, static phase, 227
 and nonesterified fatty acids, 453
 obstetric importance, *405
 and overeating, 372
 and pancreas, islet hypertrophy, 89
 tomography, *485
 and phenethylbiguanide, 274, 276, 277
 and phenmetrazine hydrochloride, *325
 and senile diabetes, *75
 and sex, 100-104
 and social problems, *405, *479
 and vascular changes, *70, *159, *480
- OBSTETRICS. See Pregnancy**, diabetic
OESTRONE, *479
OLEATE, and linoleate, 182
OLEIC ACID
 and fatty acids, *158, 198
 in peripheral vascular disease, 184
ORINASE. See Tolbutamide
OSTEOPOROSIS
 in Cushing's syndrome, 345, 346
 and diabetes mellitus, *482
OXYGEN, consumption
 from 2:4-dinitrophenol, *243
 and guanidine derivatives, 155, 156
 molecular, *241
 saturation, fetal, *324
 and sulfonylurea compounds, *241,
 *482
OXYTOCIN, secretion, 352
- P**
- PALMITIC ACID, *158**
 in peripheral vascular disease, 184
PALMITOLEIC ACID, 184
PANCREAS
 acinar cells, 37-44, *332
 acidophilic, 295
 and arylsulfonylureas, *72
 proliferation, *488
 siderophilic, 295
 and age, 83-90, *240, *483
 and body growth, 88, *320
 capillaries, and in testes, *72
 carbutamide perfusion, *321
 carcinoid tissue proliferation, 393-394
 in childhood, 85, 88, 89
 and cortisone, 89, *484
 cystadenoma, *325-326
 electron microscopy, 36-44, *332
 fibrosis, focal interstitial, 280
 function, 391
 and fat absorption, *157
 in senile diabetes, *76

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82
 July-August, 251-336

March-April, 83-166
 September-October, 337-416

May-June, 167-250
 November-December, 417-496

SUBJECT INDEX 1959

- and glucagon, 36-44, 111, 294-296,
*320, *484, *486
plasma concentration, 339
storage, *486
glycogen infiltration, *325
head, carcinoma, *399-400
and insulin, 88, 339, *479, *482
extractable, 202, 203
fluorescent antibody method, *403
and galactose, *403, 455
after hypophysectomy, 202, 204
after peripheral glucose infusion, 417
release, 455
and oral hypoglycemic agents, 55,
*240, 274, *482
synthesis, 202-204
islets of Langerhans, 36-44, *72
cell types, *332
adenoma removal, *329
and adrenal cortex, *76, *241
alpha, 37, *239, 295
/beta ratio, *75, *240, *483
degranulation, 295
functional activity, *483
and glucagon, 294, *486
and phenethylbiguanide, 154,
*239
vacuolization, 297
beta, 37, 55, *75, 86, 89, 274,
295, *325, *332, 449
and carbutamide, 55
degranulation, 41-43, *76, *325,
*404, 442, 467-470
and duodenal ulcer, 449
ergastoplasm, 42
functional activity, 422, *483
after glucagon, 37-44
lymphocytic infiltration, 86
and phenethyldiguanide, 274
and secondary resistance to oral
treatment, *321
and tolbutamide, 203
carcinoma, *487
changes, in acidosis, *75
cytology, 297, *332
and duration of illness, *76, 85,
*240, *325
formation from ductules, *488
gamma, 295
hyalinization, *76, *77, 83, *240
hypertrophy, 89
rhythmic variation in function,
*483
and size, 84
tumors, *326, *487
removal, *329
ulcerogenic factor, 111, *326
X, in glucagon-treated guinea pigs,
295
Z, *239
degeneration, 86, 89, *240, *325,
*404
and diabetes form differentiation,
*75, 89
dilation of intercapillary spaces, 41
Golgi apparatus, 37-42, *479
in insulin deficiency, *75
regeneration, 86, 89
size, 84, 89, 90
in stillborn, 49
and sulfonyleurea compounds, *321
and Synthalin, *239
volumetric distribution, *483
weight, 84, 85-86, 90
lesions, 294-296
after cobaltous chloride, 295
and lipemia clearing factor, 211-216
opacification, attempt, *488
and phenethylbiguanide, 274, *485
pneumotomographic appearance, *485
in pregnancy, 396
pyknotic nuclei, 294
removal. *See* Pancreatectomy
and tolbutamide, 201-203, 297, *332,
*482
tomography, *485
and ulcer production, 111, 449
weight, 84, 88
PANCREATECTOMY
and blood glucose, 9-10, 133, 316, *320
and corticotropin, 59-61, 139, 140
after 5-hydroxytryptamine, 394
carcinoma of pancreatic head, *399-
400
and chlorpropamide, 9-10
diabetes onset after, 300, *320, *400
and fat metabolism, *320
and hypophysectomy, 137, *241
and insulin effects, 315-316, *320, *400
blood phospholipids, 133
and growth hormone, 58
kidney lesion prevention, *486
requirements, 286-287
and ketone bodies, 133-134, 138-141,
*241, *320, *346
lipemia clearing factor, 211-216
and metabolism of baboon, *241
and nitrogen excretion, 58-61
and serum, albumin, 286
alkaline phosphatase, 285
and tolbutamide effects, 201, 285-286,
315-316
PANCREATITIS
abscess precipitation, *325
and diarrhea, 66
fat absorption, *157
and islet tissue, 83
and Kimmelstiel-Wilson lesions, *75
PANTOTHENIC ACID, *74, *76
PAPILLITIS, *75, *331
PARALYSIS
and glucose uptake, in vitro, 218-219
polysynaptic reflexes and tolbutamide,
*73
PARESES, hereditary atactia poly-
neuritiformis, *402
"PASTEUR EFFECT," 155
PEBG. *See* Phenethylbiguanide
PENTOSE
blood levels, after ribose infusions, 456
conversion to glucose, 210
metabolism, 6, 99
and insulin, 35
phosphate pathway in lipid synthesis,
457
PEPSINOGEN, blood levels, 91, 111
PEPTIC ULCER
displacement behavior, 359
and gastric hyperacidity, 111
and pancreatic tumors, 111
PERSONALITY
and diabetes management, 371-378
and oral hypoglycemic agents, 472
and presenting complaints, 289, 290,
292
and stress reactions, 379
PHENETHYLBIGUANIDE
and adrenal glands, *239, 288
amino acid deamination, 155
and blood sugar, 154-156, *242, 274-
277
and carbohydrate metabolism, 274, 277
chlorpropamide, 8, 10, 12
and tolbutamide, *479
enzymatic site of action, 155
and glucose uptake, 154-156, 171-172
and glycosuria, *242
and insulin requirements, *242
after pancreatectomy, *400
and kidney, 154, *242
in labile diabetes, *243
and pancreas, alpha cells, 154, *239
and liver, 154, 156, *242
and peripheral blood, 156, 274, 277,
278
plasma proteins binding affinity, *329
and related compounds, 154-156, *239,
*242-243
response, time factor, 276
in severe diabetes, *243, *405
side effects, *242, 274, 276, 277, *485
in unstable diabetes, *405
n- β -PHENETHYLFORMAMIDINYLMIM-
INOUREA. *See* Phenethylbi-
guanide
PHENFORMIN. *See* Biguanide
**PHENMETRAZINE HYDROCHLO-
RIDE**, *325
PHENOTHIAZINE, 353
PHENYLALANINE
metabolism, 127
protein intake and insulin, *160
PHEOCHROMOCYTOMA, 341
PHLORIZIN, 442, 446
PHOSPHATASE, alkaline
intestinal mucosa, 444
serum levels, after chlorpropamide, 10,
11
after tolbutamide, 285
PHOSPHATE
blood levels, 156
newborn infants, *77
buffer, response and anaerobiosis, *160
polyphloretin, *158
uptake after nephrectomy, *74
6-PHOSPHOGLUCONIC ACID
in arteriosclerotic tissue, *324
cycle, in mammalian tissues, 99

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

SUBJECT INDEX 1959

- oxidative decarboxylation, 341
serum concentration, *77
- PHOSPHOLIPIDS**
and cortisone, *241
and dietary fatty acids, 179
kidney contents, 133
after pancreatectomy, 133
serum content, *324
cholesterol ratio, *402
and growth hormone, 206
- PHOSPHOPYRIDINE NUCLEOTIDE**, 68
- PHOSPHORUS**
balance, in pituitary insufficiency, *401
blood content, fasting and postprandial, *238
energy rich bonds, 441
isotope labeled, 256
renal excretion, *72
retention, and growth hormone, *157
serum content, 300
and glucose uptake, *238
- PHOTOPHOBIA**, *402
- PICOLINIC ACID**, *484
- PITUITARY GLAND**
and adrenal system, 132-141, *330
assay for trophic hormones, *325
function, 232, *325
hypothalamic control, 352-357
and phenothiazine, 353
hormones, 89, 300, *324, 353, 357
ketogenic action after pancreatectomy, 132-141
insufficiency, and dwarfism, *157, *401
and hypoglycemia, *487
and insulin, 204, *401
plasma antagonistic activity, *244
toxicity, *330
and islet cell changes, *76, 89
and metabolism of baboon, *241
stalk section, 353, 356
and tolbutamide, *324
hypoglycemic effect, 199-204
- PLACENTA**
abruptio, and intrauterine death, *238
alloxan transfer, 49
endocrine function and urinary excretion, 19
neonatal difficulties, *324
and vascular lesions, 261
- PLASMA**
albumin patterns, *76, *244, *329
amino acids, and carbohydrate, *243
and exercise, *243
and carbon dioxide, *74-75
combining power, *482
chloride concentration, in ketoacidosis and/or coma, *482
cholesterol, *401
and diets, 181
esters, 182-184
and palmitic acid, 184
and palmitoleic acid, 184
electrolytes, maternal and fetal, *324
epinephrine, 339, 356
gamma globulin, *329
- glucagon concentrations, 339
glucose, 107, 339, *399, *401
after 6-deoxy-6-fluoroglucose, 113
movement between aqueous and, *401
turnover, 116, 126, 167-172
and uric acid clearance, *399
hydrocortisone, 339
and insulin, *73-74, 107, 123-126, 167-172, 213, 215
antagonists, *73, *76, 93, *244, 385
assay, *327, *330, 339
after glucose feeding, 417-423
radioelectrophoretograms, *401
radiolabeled, 308, 309
reserve index, 421
insulin-like activity, *330
ketone test, *73
lipids, 182
clearing activity, in vitro, 211-216
and dietary linoleic acid, 179
and lipocic acid, 214-216
nonesterified fatty acids, *158
and growth hormone, 232
after ribose infusion, 456, 457
17-hydroxycorticosteroid levels, *73-74, 348
osazones, 116-117, 118
phenethylbiguanide binding, *329
postheparin, and blood sugar levels, 214-216
potassium concentration, 339
in pregnancy, *73-74, *324, *399
proteins in carcinoid, 392
and tolbutamide, 167-172
determination, *72, *321
and trichloroacetic acid, 309
trophic hormone assay, *325
- PLASMINOGEN**, conversion to plasmin, *485
- POLYDIPSIA**, presenting complaint, 289, 290, 292, 374
- POLYPHLORETIN PHOSPHATE**, *158
- POLYSORBATE 80-Choline-Inositol complex**, *322
- POLYURIA**
adaptive reactions, 360
presenting complaint, 289, 290, 292
in young diabetic, 371-372, 374
- POTASSIUM**
balance, in pituitary insufficiency, *401
blood levels, 300
and carbutamide, *240
cerebral, *160, *483
chloride diuresis, in renal insufficiency, *243
dietary-restriction, and serum bicarbonate, *323
in hypoglycemic, routine management, *403
and insulin, *160, *240, 317-318, *401
radiolabeled excretion, 425
intracellular concentration, 259
loss, *160
muscle content, 317-318
in hyperglycemia, 258
and ketoacidosis, 257
- and paralysis relaxation, *160
plasma concentration, 339
renal excretion, *72
retention, and growth hormone, *157
- PREDNISOLONE**
eosinopenic time-action curve, 27
hyperglycemic potencies, 25, 26
and insulin, 428, 430
allergy, *240
- PREDNISONE**
glucose tolerance after, 3
hyperglycemic response, 25
- PREGNANCY, DIABETIC**
*See also Abortion; Fetus
acidosis, 396
albuminuria, 17
alloxan, 45-50
and carbohydrate metabolism, 395
carbon dioxide tension, *324
conjunctiva, capillary fragility index, *71
delivery, *242, *327, 322, 323, *331, 395
cesarean section, *77, *323, *327, *331, 400
late, and stillbirths, *322
premature, *77, 395-396
time for, *242, *323, 396
embryomegaly, 15, 45-50
and sex, 47
fetal loss, 46-50, *242, *323, *331, 396
intrauterine death, 19, 38, *238
premature termination, *77, 395
fetal survival, 58-59, *242, *327, *330, *331, 395
endocrine studies, 14-21
maternal age, 15
glucose, 404
prophylactic, *327
tolerance, *73, *242, 396
in prediabetic state, *330
tubular reabsorptive capacity, *399
urinary excretion, 48
hydramnios, *242, *323, *331, 396
hyperglycemia, 48-49
and illness duration, 15, 17
insulin, *323, 396
hypo-amino-acidemia, 15, *239, 396
predelivery, *327
reactivity in normal, *399
requirement, 15-16, *323
and malformation, *77, *322, *328
management, 14-21, *73, *77, *323, *327
and fetal weight, 15, 48-49, 238, *404
history, 385-386, 395
and maternal weight gain, 17
multiparity, in diabetes etiology, 100
neonatal death, 47, *327
and postnatal weight change, *400, *404
prediabetic state, 49, *330, 395
pre-eclampsia, *331, 396
and prematurity, *242, 322, *328
care as for newborn, *323, *327, 395
prenatal care, 395

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

primigravidas, *238
steroid diabetogenic action, 396
stillbirths, *322, 385-386
and paternal diabetes, *328
in rats, 45, 47-50
and tolbutamide, *239, *399, *480
toxemia, 17, *238, *242
trimester, *77
and corticoid excretion, 15-17, 396
and failure, 15, *322
unsuspected diabetes, *330, 395-396
urinary excretion patterns, 14-20
and vascular state, 15-16, 385-386
PRELUDIN. See Phenmetrazine hydrochloride
PREMATURITY
in early delivery, *322
and fetal survival, *242, *327
paternal diabetes, *328
PRESBYOPIA, *159
PRIMAQUININE, sensitivity, 288
PROGESTERONE
and alveolar gland development, *479
PROLACTIN, after hypophysectomy, 137, 140
PROPYLTHIOURACIL, 425
PROTAMINE ZINC. See Insulin
PROTEIN
and amino acid, 424
uptake, and insulin, *160
breakdown and newborn weight changes, *404
depletion, in Cushing's syndrome, 345
dietary, and ketosis, *405
electrophoretic fractions, 389-391
fetal content, *404
in alloxan diabetes, 48
and glucagon, 94
in gout, *401
metabolism, 391
glucocorticoid effects, 344-345
and myocardial oxidative process, *238
urinary excretion in pregnancy, 17-19
serum, and chlorpropamide, 10
spinal fluid, in Charcot joints, 194-195
structure, 424
synthesis, 94, 391
and insulin, 478
PROTEINURIA
in alloxan diabetes, 300
disappearance after hypophysectomy, *483
in glomerulosclerosis, 254
and phenethylbiguanide, 275
and tolbutamide metabolite, *73
PROTHROMBIN TIME
and chlorpropamide, 10
and phenethylbiguanide, 274, 277
PURPURA, after insulin, 390
PYELITIS, 391
PYLONEPHRITIS, 253-255, *331

PYODERMIA, *328
PYRIDINE NUCLEOTIDE, *76
PYRUVATE
amino acids, conversion, 156
blood concentration, 434-436
after guanidines and Synthalin, 156
conversion to acetate, *76
and fatty acid synthesis, 341
conversion to glucose, *71, 156, 344
"dicarboxylic acid shuttle" in hyper- and hypoadrenalism, 343-344
glycogen synthesis from, 344
and cortisone, 344
and epinephrine, 341
and insulin, *160, *240, *332
ketogenic potency, *76
and oxalacetate, reconversion to phosphoenol-pyruvate, 343, 344
protein uptake, *160, 391
tolerance, after phenethylbiguanide, 156
urinary, acetylation, after fructose, *76

R

RASTINON. See Tolbutamide
REFSUM'S SYNDROME, *402
RESERPINE, 353
RESPIRATORY QUOTIENT
and growth hormone, 208
and hypothermia, *158
RETINITIS, 275, *328, 385
RETINOPATHY
arterial disease, 174
and blood protein-bound hexose levels, 174-178
and Charcot joint development, 192, 194-195
diagnosis, 174
and diet, 197
fatty acids, 185
and duration of illness, 93, *328, 385, *480
and gangrene of lower extremity, 267, 268, 270
and glucose tolerance tests, *480
and hypophysectomy, *483
incidence, *159
insulin, 268
antagonist, 93
requirement, 197
and juvenile onset, 93, *484
lesion absence in dog, 300, 304
and renal disease, 270-271, *405
See also Kimmelstiel-Wilson syndrome
retina detachment, 385
and thyroid function, *400
vascular lesions, 261
and vitamin B₁₂ treatment, *484
RIBOSE
and blood glucose, 456, 457, 458
hypoglycemic effect, 455
intestinal absorption, 444
metabolism, 455-458

and pancreas insulin release, 455
and plasma nonesterified fatty acids, 456, 457
renal tubular reabsorption, 457
urinary excretion, 456-458
ROENTGENOGRAPHY, body density, *239
RP 2254. See Sulfaisopropyl-thiadiazole
RP 2259. See Glipasol

S

SACCHARIN, hypoglycemic effects, *405
SALICYLATES, *160, *243
SATIETY
glucostatic theory, 227-228
and hunger, 226-230
See also Hunger
in hypothalamic-hyperphagic mice, 227
and operant conditioning, 226
SCHILLING TEST, 64, 66
SECRETIN TEST, *157
SERINE, *160
SEROTONIN, 393, 394
SERUM
albumin levels, 10, 286, 438-440
in glomerulosclerosis, 253-255
alkaline phosphatase, and oral agents, 10, 274-277, 285
amino acids, *240
amylase level, in carcinoid, 394
bicarbonate, and adrenocortical hormones, *323
calcium concentration, 300
in Charcot's disease, 193
and chlorpropamide, 8
in depancreatized animals, 9-12
cholesterol concentration, *242, 274, 277, 285, *405, *484
and age, *331, *486
after carbutamide, *323
coronary heart disease, *331
and cortisone, *241
familial tendency, 180
and polysorbate 80-choline-inositol complex, *322
and Safflower oil-sitosterol-pyridoxine, *242
after sucrose and glucose, *401
and vascular changes, *159, 181, 385, *402, *486
electrophoresis, 385, 438-440
fractions, 10, 193, *243, 385, 438-440, 525-530
after adrenocorticotrophic hormone, *484
in atherosclerosis, *402
carbohydrate binding, *402
gamma globulin, *322
antibody, *329
hemagglutination reaction, *328
protein-bound iodine, 277
and glucose, 257, *238
uptake, 438-440
See also Blood sugar

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 251-336

March-April, 83-166
September-October, 337-416

May-June, 167-250
November-December, 417-496

SUBJECT INDEX 1959

- and growth hormone, 207, *484
5-hydroxytryptamine levels, 393
and insulin, *238, *243, *484
 assay, *327
 binding, *242, *329, 430
 inhibitory substances, *329, 386
 -like activity, 29-34, 438-440
 specificity, 34, 438-440
isocitric dehydrogenases, *77
ketone bodies, *402, *403
lipids, 207, *402, *486
 in alloxan diabetes, 300, 303-304
 and electric convulsive therapy, *324
 transport and fat absorption, 209
 and vascular change, 385
nonesterified fatty acids, 207
after phenethylbiguanide, 274, 277
phosphate, after D-xylose, 210
6-phosphogluconic dehydrogenase, *77
phosphorus, *238
 in severe neuropathy, 64
potassium level, and paralysis, *160
sialic acid binding, *402
sodium, osmolar concentrations, 257
after thyroid stimulating hormone,
 *484
after tolbutamide, *240, 286
 and pancreatectomy, 285
transaminase, tests, 274, 275, 285
urea nitrogen, 254
vitamin B₁₂ concentrations, *70
zinc content, *76
- SHOCK**, after dodecamethylenediguanidine, *239
- SIDEROSIS**, nutritional, 306
- SKIN**
 in Charcot's disease, 192
 gangrene, 266-268
 heredopathia atactica polyneuritiformis,
 *402
 insulin reactions, 389-391
 isotope clearance, *238
 protein depletion in Cushing's syn-
 drome, 345
 side effects, oral agents, *479
 temperature test, 64
 types of lesions, *327
- SMOKING**, hypoglycemia, *479
- SODIUM**
 arsenate, *160
 azide, *160
 blood content, in degenerative lesions,
 300
 excretion, *72
 in threatening situation, 360-361
 in ketosis, 257, *326
 muscle content, 257
 in hyperglycemia, 258
 octanoate, *326
 and picrotoxin convulsions, *483
 retention, *77
 and growth hormone, *157
- SOMOGYI-NELSON**. *See* Nelson-Somogyi tests
- SORBITOL**
 colorimetric determination, *479
 enzymatic determination, *332
- SPHEROCYTOSIS**, hereditary, 127
- SPINAL CORD**
 focal myelomalacia, 280, 281
 insulin action, *160
 polysynaptic reflexes and tolbutamide,
 *73
- STADIE**, William C., 472, 476-478
- STEARIC ACID**, 184
- STEROIDS**
 adrenal, 356, *483
 and carbohydrate metabolism, 109
 metabolic removal in obesity, *330
 and vascular complications, 347
 ketogenic, *75, 396
 urinary excretion, *75
 in diabetic pregnancy, 17, 19
 after insulin, *483
- STONE**, George F., 397
- STREPTOKINASE**, *485
- STRESS**
 and acidosis, 372, 380
 adaptive response, 358-363
 and adrenal cortex, 348
 corticotropin secretion, 353
 and hypothalamic lesion, 354
 and pituitary stalk section, 353, 356
 diuresis, 359-362
 and glucose excretion, 360-361
 and ketonemia, 361
 pregnancy, and carbohydrate metab-
 olism, 396
 self-destructive behavior, 379, 380-381
 in unstable diabetes, 371-378
- SUCCINIC ACID**
 and choline, hypoglycemic reversal
 with, *484
 formation from pyruvate, 344
 and phenethylbiguanide, 156
- SUCROSE**
 blood-sugar response, *321
 dietary, and plasma cholesterol, *401
- SUGAR**
 See also Blood sugar; Glucose; and
 specific substances
 absorption, 442-447
 muscle permeability, 224
 transport, 442-447
 blood brain barrier, 457
 and cell membranes, 445-446
 dephosphorylating enzyme, 444
- SULFANILAMIDE**, 288
- SULFANILYL-BUTYLCARBAMIDE**.
 See Carbutamide
- SULFOBENZOIC ACID IMIDE**, *405
- SULFONAMIDES**. *See* Sulfonamides;
 and specific substances
- SULFONAMIDOTHIAZOLE**, *332
- SULFONYLBUTYLUREA**, *241
- SULFONYLUREAS**
 See also specific substances
- and blood sugar, *238, *244, *332,
 473
hypoglycemic action, *158, *326, 472-
 473
 in Addison's disease, *241
 and carbohydrate metabolism, 274,
 277, 370, 472-473
 and diabetic coma, *241
 and structure, *241
and insulin, *244
 pretreatment, *332
 production of endogenous, *329
 release, 202
 requirement, 154, *159, *241, *243,
 276, 277, *324, *331, 365-
 367, *403, 472, *488
isopropyl, *241, *485
in juvenile diabetes, *241, *244, 364
and ketosis, *74, *244, 473
 acidosis, *241
 and muscle metabolism, *241
 pancreatic action, 202, *321, *485
 plasma binding affinity, *329
 potency, *238-239
 secondary failure, *332, *481
 selection for therapy, *238, *241, *244,
 *326, *329, 472-473
side effects, 13, *159, *241, *242-243,
 *244, 276, 277, *331, *479,
 *485
tests, *244, *331-332, *472-473
usage review, *158, *241, *329
- SULPHONILYL-BUTYLCARBAMIDE**.
 See Carbutamide
- SURGERY**
 and acidosis, *239, *399
 keto-, *400
 and carcinoma, *239
 of pancreas, *399-400
 electrolyte balance, *479-480
 in gangrene, *239, *399
 gastric, *487
 hypoglycemic reaction, *239
 functional, *487
 insulin pretreatment, *244
 in neuropathic joints, 195
 selection for, *480
 for vascular complications, *241
 See also Adrenalectomy; Hypophy-
 sectomy; Pancreatectomy
- SYNTHALIN A**. *See* Decamethylenedi-
 guanidine
- SYNTHALIN B**. *See* Dodecamethylene-
 di guanidine

T

- TEMPERATURE**
 environmental, and ketosis, *405
 and muscle potassium movement, 317
 and sugar transport, 442
- TES-TAPE**, false-positive urine tests, *72,
 *75, *160
- TESTOSTERONE**, urinary excretion, 17-
 19

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 251-336

March-April, 83-166
September-October, 337-416

May-June, 167-250
November-December, 417-496

SUBJECT INDEX 1959

TEIRAETHYLAMMONIUM BROMIDE, *159

THERMOSTATIC THEORY, 228

THROMBOANGIITIS OBLITERANS, 262, 267

THROMBOSIS

cerebral, and insulin resistance, *485
and gangrene of heel, *239
idiopathic, 262, 267

THYROID GLAND

function, 274, 277, 353, 444
assay, *400

and phenethyldiguanide, 274, 277
and glucose absorption, 444
and growth, *401
and metabolism of baboon, *241
and serum cholesterol, *323
and systolic pressure, *74

THYROID STIMULATING HORMONE, 134, 137, 140

THYROTOXICOSIS, *75

THYROTROPIC HORMONE, *324, 444

after hypophysectomy, *325
after pancreatectomy, 61
production by diabetic mother, *329

THYROXINE

and glucose, absorption, 444
and tolbutamide, *324

TISSUE

adipose, *332, *401
in dynamic and static hyperphagic animals, 229
and epinephrine, 340, 341
fatty acids, 340, 341
and glucocorticoids, 346
glycogen and fat synthesis, 478
and growth hormone, 232
metabolism, 340, 341, 346, 391
and phenethylbiguanide, 154
epididymal, 29, 33, *330, *332, 461-462
glucose uptake, 30-35
and serum protein, 438
and insulin, 30-35, *321, *332, 341, *401, 478
content after death, *70, *71
lipids. *See* specific sites

TOLBUTAMIDE

and adrenal medulla, 200, 203
and age factor, *159, *241, *244, 366, 367, 378
and amino nitrogen, *399
and beta cells, 203, 470
and blood potassium, *240
and blood sugar, 2, 8, *159, 203, *240, *241, *244, *332, 365-367, 467-470, *482
and adrenalectomy, 200
and amino acids, *239
after glucose ingestion, 418-423
and hypophysectomy, 199-202
and carbutamide, 8-12, *241, *403
and chlorpropamide, 1-12, *238, *239, *241, 364-367, *479

and curare, *324
and diet, 197, *244
and diguanide compounds, *403, *479
dose-response relationships, 8, *73, *241
and epinephrine, 203
failures, *241
and carbohydrate metabolism, 420
secondary, *321, *481
and Glipasol, *481
and glucose, in fasted animal, 461-471
plasma turnover, 167-172
glycogenolytic effect, *324
and hyperglycemia, *241, 364-367
hypoaminoacidemia development, *239, *480
hypoglycemic responses, 8, 199, *239, 369, 466, *480
and chlorpromazine, *73
time factor, 202-203
and infection, 366, 368
and insulin, *77, *158, *159, 167-172, 199-203, *239, *241, 285-287, *482, *487-488
degradation, 311, 313
after pancreatectomy, 315-316, *400
reserve index, 421-423
substitution for, *158, 197, *240, *400
and lactate concentration, *240
and liver, 311
glycogen, 470
parenchyma, *481
metabolites and false positive protein reactions, *73
and neuropathy onset, *322
and pancreas, 284-287
perfusion, *321
tomography, *485
"Pasteur effect," *482
and phenethylbiguanide, *479
pituitary role in response, 199-204
plasma concentration
determination, *72, *321
kinetics, 167-172
poisoning, *403
in pregnancy, *239, *399, *480
and pyruvate concentration, *240
selection for therapy, *480, *488
side effects, *73, *77, *241, *323, *403
and somatotropin, *404
structural formula, 7
tolerance test, 396
in severe diabetes with remission, 189-191
TOMOGRAPHY, of pancreas, *485
TRICHLOROACETIC ACID, 308, 425
and insulin, *401
TRIGLYCERIDES. *See* Lipids
TRIIODOTHYRONINE, 457
TRIOLEIN TOLERANCE TEST, 64
TRIPHOSPHOPYRIDINE NUCLEOTIDE
and adipose tissue metabolism, 341
cholesterol and hepatic synthesis, *244
and fatty acids, 68

and glucose-6-phosphate oxidation, 341, 343
and hepatic lipid synthesis, *244
TUBERCULOSIS, and diabetes, *71, *77, 473-475
TWINS, glucocorticoid responses, 25
TYROSINE, and insulin, 311-313
and phenylalanine, 127

U

U-2043. *See* Tolbutamide

ULCERATION

duodenal, 91
and hyperinsulinism, 449
foot, *325
toes, 192, 193
and pancreatic juice loss, 449
peptic, 111
as displacement behavior, 359

UREA

clearance, in glomerulosclerosis, 253-255
in neuropathy, 64, 193
production, after biguanides, 154, 156, 275

UREMIA, and retinopathy, *328

URINE

acid excretion, after nucleoprotein breakdown, *401
and plasma glucose concentration, *399
adrenalin excretion, *158
albumin, 193
in renal disease, 174
androsterone, 17-19
arabinose assay, *400
carbohydrate excretion, *400
in Charcot's disease, 193
after chlorpropamide, 1
cobalt-treated guinea pigs, 295
etiocholanolone, 17-19
excretion patterns, in pregnancy, 14-20
See also specific substances
flow, adaptive reactions, 360-361
formaldehydehydrogenic steroids, 17
galactose assay, *400
17-hydroxycorticoid excretion, 16, *330, *483
and phenethylbiguanide, 277
5-hydroxyindoleacetic acid, 392
in hyperthyroidism, *158
 α -ketoglutarate in uncontrolled diabetes, *76
ketones. *See* Ketonuria
17-ketosteroids, 17, 64, *74, 277, *483
lactose assay, *400
nitrogen concentration, 58, 59-61, 344
pentose concentration, 99
after ribose infusions, 456, 457
presenting complaint, 289, 290, 292
pyruvate, *76
sugar content, *400
and aging, *76
in alloxan diabetes, 48, 300
in carcinoid, 392-393

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

SUBJECT INDEX 1959

- and chlorpropamide, 365
cobalt-treated guinea pigs, 295
and corticotropin, 59-61
and diabetes duration, *76
after glucagon, 37-44
and glucocorticoid, 346
after glucose, 468
after glycogen, 95
and growth hormone, 58
and hypothermia, *158
loss in Addison's disease, *482
and oral hypoglycemic agents, 473
See also specific substances
after pancreatectomy, 59-61, 133
and ribose, 456, 457, 458
See also Glycosuria
tests, *400
Benedict's, 7
false-positive, *72, *75, *160
Froesch and Renolds, 95
and insulin Lente, *404
and tolbutamide metabolites, *73
and thyroid function, *400
and tolbutamide, *73, 365
uropepsin after insulin, *483
volume, 289, 290, 292, 360, 371-372,
374, 468
water excretion, 360-361, *404
xylose, 210, *400, 457
zinc excretion, *76, *480-481
- UROPEPSIN, *483
- V**
- VAGINITIS, 291
- VASCULAR DISEASE. *See* Blood vessels, diseases
- VERONAL, *73
- VISION. *See* Eyes
- VITAMIN
B₁, 471
and ketone body excretion, *74
B₆, 471
B₁₂, *70
- and retinopathy, *484
and enzyme systems, 378, 471
in hypoglycemia, *403
- VOMITING
cyclic, and blood sugar, *240
and hypoglycemia, *71
presenting complaint, 289, 290, 292
side effect, *242-243, *331, 390, *485
- W**
- WATER, BALANCE
in acidosis, *486
and blood sugar, 259
Courtice-Douglas effect, *404
and electrolyte changes, *327, *328
and environmental temperature, *404
and excretion, *404
in threatening situation, 360-361
after glucose, *327, *328
and muscle content, 258
and ketosis, 257
in newborn infant, *404
- WEIGHT
See also Obesity
and carbohydrate metabolism, 104,
*323
after carbutamide, 53
and chlorpropamide, 364
and diet, 51-55, 103, 227, *321, 370
and elaidate, 198
and energy balance, 227
fetal, 15, 48-49, 238, *404
paternal diabetes, *328
and sex, 47
and food quantity, 226, 227
forced feeding, *479
gain, 55
and Safflower oil-Sitosterol-Pyridoxine, *242
and growth hormone, 58, 207
hemidiaphragms, after denervation,
221, 222
and insulin, 53, 133
- linoleate and linolealaidate, 198
and linseed oil, 198
loss, 53, *323
and biguanide therapy, *243
in carcinoid, 392-393
and corticotropin, 59-61
and 2-deoxy-D-glucose, *325
and glucagon, 41, 43
after glucose, and tolbutamide, 467
and islet cell changes, *75
and phenmetrazine, *325
presenting complaint, 289, 290, 292
maternal gain, 17
and nitrogen storage, 58
and phenethylbiguanide, 276
postnatal changes, *400, *404
reduction, 104
in obese diabetic, *323, 372
and vascular complications, *71
- X**
- XANTHOMA, *327
eruptive, *403
and ethyl linoleate, 181
and linoleic acid, 181
and plasma lipid, 181
- D-XYLOSE
and blood sugar levels, 210
distribution and insulin, 35
phosphorylation, 443
urinary excretion, 210, *400, 457
- Y**
- YEAST, 443
and fatty acid, 115
- Z**
- ZIMMERMAN'S REAGENT, 19
- ZINC
liver content, *76
urinary excretion, *76, *480-481

Erratum

In the abstract of an article by Oliver E. Turner, entitled "Diabetes—an Increasing Problem," which appeared on page 511 of the November-December 1958 issue (Volume 7, Number 6), the first sentence should read: "It is well to remember that in 1920 diabetes was the twenty-third leading cause of death in the United States." Through error the date was given as 1950 instead of 1920.

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

AUTHOR INDEX 1959

In this index are the names of authors of articles which have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1959. Entries marked with an asterisk (*) indicate authors of material which appeared in the ABSTRACTS only. For subject index see page 1.

A

Abraham, Albert, *331
Ahren, Kurt, *479
Aktan, Hamdi S., *157
Alert, Hal A., 466-471
Alex, Morris, 261-273
Allan, J. C., *241
Allwood, M. J., *238
Almasy, F., *480
Altszuler, N., 105-111, *320
Ambrus, S., 105-111
Amil, Manuel, *487
Anderson, George E., *326
Anderson, Robert C., 7-13, *71
Annino, Joseph S., *238
Arai, Y., *72
Argyris, Bertie F., *320
Arnhold, R. G., *77, *162
Asch, Thane, *485
Assevero, Victor L., *157
Askanazy, C. L., *157
Athanas, George, *70

B

Babbott, David, *243
Bailey, J. Martyn, *479
Baker, Eugene M., 455-458
Baladi, Kamel, *320
Balodimos, Marios C., 196-198
Banner, Edward A., *238
Barber, Donn J., *157
Bassett, David R., *324
Bassoe, Hans H., *70
Bastenie, P. A., *238
Batts, Adrienne A., *479
Beardwood, Joseph T., Jr., *239, 397
Beaser, Samuel B., *479
Beatty, Clarissa H., *479
Beaven, D. W., *70
Beck, John C., *157, *325
Beigelman, Paul M., 29-35, 438-441
Bell, George E., *73
Bellet, Samuel, *324
Bennison, B. E., *479
Berezin, Abraham, *399
Bemasconi, C., *402
Berry, Maxwell G., *479
Berryman, George H., *242, *479
Berson, Solomon A., 116-127, *157
Best, C. H., 284-288
Beutler, Herbert K., *238
Bhattathiry, E. P. M., *242
Bickford, A. F., *157
Bierman, Edwin L., 455-458
Bing, R. J., *238

Birchall, I., *238
Birkinshaw, V. J., *70
Bjerknes, C., 105-111
Björkstén, G., *483
Bland, James L., 51-56
Bloedow, Carman E., *238
Bloom, Arnold, *159
Bloom, Walter Lyon, *70
Blumenthal, Herman T., 261-273
Bocek, Rose Mary, *479
Bockman, Albert A., *242
Boehm, John J., 289-293
Boger, William P., *70
Bogoch, A., *481
Bolinger, R. E., *77, *239
Bomford, Richard R., *241
Bornstein, J., 92-93
Bothe, Frederick A., *239, *399, *479
Bowyer, Freda, *158
Bradley, Robert F., *324
Brahén, Louis J., *320
Bregman, E., *484
Brown, Donald W., *480
Brozek, Josef, *239
Brundstrup, N., *324
Bryan, George T., *320
Bryant, David M., Jr., *240
Bubnoff, M. von, *327
Buckley, R. E., 167-173
Burrows, Ruth E., *323
Burt, Richard L., *239, *399, *480
Buscarini, L., *402
Buschmann, G., *70, *480
Buse, John, 218-225
Buse, Maria Gordon, 218-225
Butler, Frank K., *332
Butterfield, W. J. H., 450-454

C

Cabaud, Philip G., *70
Cahill, George F., Jr., 337-349
Calvin, James L., *399
Campbell, J., 205-210
Campbell, P. N., *76, *244
Cantor, Edward B., *320
Cardeza, A. F., 36-44
Cavallero, Cesare, *320
Chen, K. K., *71
Chernick, Sidney S., 132-142, *161, *320
Chimènes, Hubert, *320
Chin, H. P., 179-188
Choudhury, J. D., *238
Christensen, P. J., *399
Christophe, Jean, *399
Chulski, Thomas, *321
Ciminera, J. L., *70

Coehlo, M., 179-188
Cohen, William Coleman, 63-67
Collens, William S., *480
Colwell, Arthur R., Jr., *321
Colwell, John A., *321
Conklin, J., 179-188
Conn, Jerome W., *482
Constam, G. R., *480
Contopoulos, A. N., *325
Cook, C. A. G., 174-178
Cook, P. H., *71
Cori, Carl F., *403
Cornatzer, W. E., *482
Corvilain, J., *330
Cosnett, J. E., *321
Covian, Miguel R., *399
Craig, Carol E., *399
Craig, J. W., 432-437
Crawford, Susanne, *159
Creutzfeldt, Werner, *239, *399
Curry, A. S., *70

D

D'Amico, Giuseppe, *240
Danforth, Elliot, Jr., *481
Date, J. W., *400
Davies, J., *403
Davis, M. Edward, 14-21
Davis, Neil C., *485
Davis, T. W., *481
de Bodo, R. C., 105-111, *320
DeCosta, Edwin J., *327
DeMeutter, Roger C., *239
Dennes, Elizabeth, *76, *244
Diamant, E. J., *71
Diller, W. F., *158
Dimitrakis, M., *484
Ditzel, Jörn, *71, *74, *328
Dobkin, Gerald B., *480
Dobrzanski, T., *481
Dobson, Harold L., *403
Dodds, Sir Charles, *321
Dotevall, Gerhard, *321
Douthwaite, A. H., *400
Downie, Ewen, 383-387
Doyle, E. M., *404
Drakontides, A. B., *484
Drucker, W. R., 432-437
Drury, Douglas R., *77, 112-115
Dulin, W. E., 199-204
Duncan, Garfield G., 364-367
Dunn, A., 105-111, *320
Durandy, G., 105-111
Dyrbye, M. O., *321
Dyrenfurth, I., *157

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

AUTHOR INDEX 1959

E

- Easley, Albert S., *158
- Elias, Arthur W., *331
- Ellenberg, Max, *158, 279-283, *322, *400
- Elrick, H., *72
- Enerson, Daniel M., *403
- Engel, Frank L., *326
- Epstein, Edward, *241
- Eusebi, A. J., *244

F

- Fagan, Violet M., *161, *243
- Fahrenbach, M. J., *401
- Fairweather, F. A., *321
- Fajans, Stefan S., *482
- Fancher, Otis E., *73
- Farquhar, James F., *400
- Fee, Beverly A., *486
- Feinberg, Arthur W., *481
- Felber, Jean-Pierre, 94-99
- Feldman, Harold, *486
- Felts, John H., *400
- Fenton, E. L., *322
- Ferguson, James Henry, *323
- Ferner, H., *72
- Field, James B., *76, *322
- Fischer, Alfred, 371-378
- Fleming, David G., *75
- Fleming, J. Will, Jr., *158
- Florsheim, Warner H., 388-391
- Flynn, P., 179-188
- Foa, Piero P., *240
- Fodden, John H., *322
- Forist, Arlington A., *72
- Frazer, S. C., *72
- Fredrickson, Donald S., *158
- Free, Alfred H., *73
- Freinkel, Norbert, 459-465, *482
- Frenger, W., *328
- Friedlander, Ernest O., *240
- Fritze, E., *70, *480
- Fry, I. Kelsey, 174-178
- Fukayama, G., 179-188
- Fuller, Harvey L., *322
- Fulton, Richard L., *73

G

- Gaal, Stephen A., *479
- Gaebler, O. H., 57-62
- Galansino, Giorgio, *240
- Gamble, James L., Jr., *323
- Gammon, L., 179-188
- Garland, Hugh, *401
- Gastineau, Clifford F., *482
- Geld, H. v. d., *77
- Gellis, Sydney S., *322
- Gellman, Derek D., 251-256
- Gepts, W., *240
- Gerbie, Albert B., *327
- Gerstenberg, E., *73
- Gerstenfeld, B. S., *75
- Gerszi, Kornell E., *487
- Geyer, Robert P., *405
- Gilbert, Christine, *241
- Giles, Kenneth M., *401
- Gillespie, Luke, *323

- Gillman, Joseph, *241
- Gitelson, Simon, *404
- Gittler, Robert D., *482
- Glovinsky, Rachel, 57-62
- Goebert, Herbert W., Jr., 315-316
- Goldenberg, Sidney, 261-273
- Goldfarb, June L., 211-217
- Goldner, Martin G., *158
- Goldwasser, H. V., *330
- Gomberg, C., *242
- Goodlin, Robert C., *324
- Goodman, Joseph I., *401, *482
- Goodner, Charles J., 459-465
- Gordon, Robert S., Jr., *158
- Gourley, D. R. H., *241
- Grant, W. C., *401
- Granville-Grossman, K. L., *159
- Grayson, J., *159
- Greenbaum, D., *241
- Greenberg, Philip, 1-6
- Greene, James A., *403
- Grodsky, G. M., *482
- Groen, J., *77
- Grollman, Arthur P., *323
- Guarco, Barbara A., 132-142
- Guillemin, Roger, 352-357
- Gurd, M. R., *70

H

- Hall, William H., 455-458
- Hamwi, George J., 274-278, *401
- Hanus, Y., 284-288
- Harris, John E., *401
- Harris, Paul N., *71
- Hartel, Gottfried, *323
- Hasselblatt, A., *73
- Hauz, E. A., *241, *482
- Havener, William H., *159
- Hayes, Jesse D., 189-191
- Hayles, Alvin B., *401
- Heale, T. A. F., *73
- Heimback, Dennis P., *330
- Heiskell, Charles L., 388-391
- Helander, Einar, *482
- Heller, N., *159
- Hellerström, Claes, *483
- Hellman, Bo, *483
- Helmreich, Ernst, *403
- Henderson, Theodore A., *239
- Henley, Elaine D., *332
- Henn, Mary J., *241
- Hennes, Allen R., *241, *401
- Herman, Joseph B., *401
- Hernberg, C. A., *483
- Heycock, J. B., *402
- Himwich, Williamina A., *483
- Hinkle, Lawrence E., Jr., 371-378
- Hlad, C. J., Jr., *72
- Hodgkinson, C. P., *331
- Hodt, Joseph, 94-99
- Hoffman, M. M., *159, *162
- Hofstetter, J. R., *241
- Holman, Gerald H., *162
- Hsea, David Yi-Yung, *322
- Huffman, E. R., *72
- Hungerford, Gerald F., *402
- Hunter, Warren C., *488
- Hurley, Nancy, *405
- Hyde, Deirdre, 92-93

I

- Ingbar, Sidney H., *482
- Introzzi, P., *402
- Ishihara, Ichiro, *483

J

- Jackson, Robert L., *402
- Jaeger, D. A., *484
- Janes, Ralph G., 466-471, *484
- Javid, Hushang, *331
- Jenkins, L., *157
- John, Henry J., *73, *323, *402
- Johnson, R. E., *402, *404, *405
- Johnston, Dewey W., *403
- Johnston, Robert L., *241
- Jones, F., *74
- Jones, Howard W., Jr., *162
- Jones, O. Hunter, *323
- Joshi, Ram A., 261-273
- Joslin, Elliott P., *323
- Jost, Franz, *323

K

- Kadota, Ichiro, *484
- Kägi, J. H. R., *76
- Kaiser, Irwin H., *324
- Kako, K., *238
- Kalant, N., *159, *162, *242
- Káldor, Antal, *324
- Kanameishi, Doris, *240
- Kark, Robert M., 251-256
- Katims, Robert B., 425-431
- Kaulbach, Maximilian, *326
- Kawachi, Yoshimi, *484
- Keen, Harry, 392-394
- Kempner, Walter, *324
- Kerby, Gerald R., *403
- Kern, Ernst, *399
- Kerr, R. B., *481
- Kershbaum, Alfred, *324
- Kesson, C. W., *403
- Keys, Ancel, *239
- Khachadurian, Avedis K., *239
- Kilpatrick, R., *158
- Kimmel, J. R., *486
- Kinch, Robert A. H., *242
- King, Edward J., *405, *486
- Kinnear, T., *159
- Kinsell, L. W., 179-188
- Kipnis, David M., *403
- Kirk, J. E., *324
- Kirk, Robert D., *239
- Klimas, John E., Jr., *159
- Klotz, Arthur P., *157
- Knowles, Harvey C., Jr., 371-378
- Koenig, Robert P., *73
- Komori, Yoshitaka, *483
- Komerup, Tore, *484
- Koszewski, Bohdan J., *324
- Kovacs, Leslie L., *486
- Krainer, Leo, 279-283
- Krahl, M. E., *484
- Krake, John, *72
- Krall, Leo P., *324, *332
- Krogh, Hans-Kr., *70
- Kruger, Fred A., 274-278
- Kümmerle, Fritz, *399

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

July-August, 251-336

March-April, 83-166

September-October, 337-416

May-June, 167-250

November-December, 417-496

AUTHOR INDEX 1959

Kushner, Daniel S., *324
Kuwayti, K., *403

L

Lacy, Paul E., 36-44, *332, *403
Landau, Bernard R., *325
Larson, Carroll B., *325
Larson, Ellen R., 112-115
Larsson, Yngve, *159
Lawrence, A. M., *325
Lawrence, R. D., *403
Lax, Henry, *481
Lazarus, Sydney S., *76, 128-131, 294-297, *325, *484
Leemann, W., *480
Lees, F., *75
Leevy, Carroll M., 1-6
Leftin, Jehudah H., *74
Leith, W., *325
Lendle, L., *484
Leonards, Jack R., *485
Levine, Rachmiel, *329
Lewis, J. G., *159
Lewis, Lena, 205-210
Linton, Robert R., *325
Lints, H., 298-306
Lipscomb, Harry, *403
Litchfield, J. A., 257-260
Little, Brian, *73
Lofaro, Patricia, 294-297
Lombard, Herbert L., *323
Lonergan, Peggy, *325
Lowrie, W. L., *331
Lubs, Herbert A., *325
Lucariello, Ralph J., *486
Ludin, Hans, *485
Lukens, Francis D. W., 476-478
Lynch, Matthew J. G., *75

M

Macaulay, Alice, *331
MacGregor, Kenneth H., *326
Maclean, Neil, 83-91
Macy, Dorothy, Jr., *403
Maddox, J. Kempson, *74
Madison, Leonard L., *487
Maduros, William, 251-256
Magee, D. F., *488
Makman, Maynard H., *326
Makman, Richard S., *326
Malinow, Manuel R., *326
Manchester, K. L., *160
Manning, Miriam D., *323
Marble, Alexander, *239, *326, *485
Marks, Leon J., *74
Marsch, A., *70, *480
Martin, Frances B., *332
Martin, F. I. R., 383-387, *485
Maskaleris, Thomas G., 57-62
Mayer, Jean, *399, *405
Mayo, Henry W., Jr., *403
McC Campbell, Stanley R., *162
McCarthy, H. H., *74
McCowan, Max C., *71
McCullagh, E. Perry, *486
McDonald, Hugh J., *329
McGarry, E. E., *157

McKendry, J. B. R., *403
McLeod, Josephine, 294-297
McNeal, E. R., *399
McPherson, Harry T., *326
Meier, Hans, *403
Meister, Lester, 388-391
Meltzer, Lawrence E., *242
Meng, H. C., 211-217
Meschan, I., *400
Meyers, V. W., *74
Michaels, G. D., 179-188
Michal, G., *238
Migliorini, Renato H., *399
Miller, A. L., *321
Miller, M., 432-437
Miller, William L., Jr., *72, 199-204
Mirsky, I. Arthur, *404, *485
Mirsky, Stanley, *328
Mockel, G., *328
Moench, A., *239
Monaco, Robert N., *326
Monkhouse, F. C., 284-288
Moore, Richard O., *481
Mori, Hiroyoshi, *239
Moriwaki, T., *74
Morrison, Ashton B., *161
Mortimore, Glenn E., 167-173, 307-314
Moss, James M., *157
Mottram, R. F., *157
Muehrcke, Robert C., 251-256
Muhler, Joseph C., *488
Muirhead, E. E., *74
Mukherjee, B., *485
Mulder, Donald W., *326
Murdaugh, H. V., Jr., *404
Murphy, Douglas P., *328
Murray, David B., *74
Murray, Ian, *242
Murrell, L. R., *404
Myers, Jack D., *326
Myhre, J. R., *404

N

Nace, Paul Foley, *404
Nagelsmit, W. F., 100-104
Nakada, Henry I., 112-115, *329
Narahara, H. T., *326
Nath, M. D., *242
Newcomb, Alvah L., 289-293, *404
Nichols, George, Jr., *486
Nichols, Nancy, *486
Nichols, T. R., 174-178
Nissen, Nis I., *486
Nomland, Ruben, *327
Nugent, Mary A., *75
Null, F. C., *486

O

Oddie, T. H., *400
Odell, William D., *242
Offerijns, F. G. J., *160
Ogilvie, Robertson F., 83-91
Oji, K., *74, *76
Olson, F., 179-188
Onoprienko, Ilarion S., 438-441
Osler, Mogens, *404
Owen, John A., 51-56

P

Paley, Ronald G., *327
Pascullo, Marguerita, 116-127
Passmore, R., *402, *404
Pattee, C. J., *330
Patterson, Jean, 205-210
Paul, Norman D., 466-471
Pearson, Carl M., *404
Pedersen, Jørgen, *404, *486
Pedowitz, Paul, *327
Peng, C. T., *482
Perisutti, Gladys, *404, *485
Perkoff, G. T., *486
Perret, James T., *488
Peschel, Ruth Lohmann, *324
Petersen, E. S., 298-306
Peterson, R. D., *479
Petraglia, Samuel, *244
Phillips, Alec, *75, *160
Piazza, Eugene U., 459-465
Pirani, Conrad L., 251-256
Plotz, E. Jurgin, 14-21
Plough, Irvin C., 455-458
Pogátsa, Gábor, *324
Pomerance, Julius, *405, *486
Porter, Eleanor, 218-225
Power, Marschelle H., *401, *482
Price, D. E., *70
Prout, Thaddeus E., 425-431

R

Radding, Robert S., *405
Rado, Peter P., *403
Rafaelsen, Ole J., *160
Rambert, Paul, 234
Ramel, Cl., *241
Randall, S. S., *70
Randle, P. J., *160, *161, *243, *327
Raphael, Stanley S., *75
Read, Charles H., *320
Reid, James, *243
Reilly, W. A., 167-173
Reinwein, H., 398
Reis, Ralph A., *327
Relman, Arnold S., *238
Renold, Albert E., 94-99, *332, 337-349
Ricketts, Henry T., 14-21, 298-306, *405
Riddell, M. J., *242
Riecker, G., *327
Rimer, David G., *404
Robbins, E., *405
Robbins, Stanley L., *325
Robertson, S. E. J., *75
Robinson, R. R., *404
Rodríguez, Ricardo R., *486
Root, Howard F., *328
Root, Mary A., 7-13
Rose, C. F. M., *321
Rosenthal, F. D., *75
Rossi, E., *486
Rossi, Evangeline, *73
Rossmel, Elsie C., *74
Roth, Arthur A., *75
Rubin, Alan, *243, *328
Rubini, Milton E., *243
Rushton, Joseph G., *326

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

S

Saifer, Abraham, *75
 Saka, Yukio, *483
 Sarcione, Edward J., *161
 Sargent, F., II, *402, *405
 Sawyer, L., *405
 Scheiffarth, F., *328
 Schlayer, Clotilde, *324
 Schless, Guy, 450-454
 Schmidt, G., *73
 Schneider, J. A., *484
 Schucher, R., *242
 Schumacher, O. Peter, *486
 Schuster, R., *73
 Scohy, L., *330
 Scott, C. C., *331
 Scott, Mary H., *327
 Scow, Robert O., 132-142, *161, *320
 Searle, G. L., 167-173
 Searle, Gordon W., *159
 Seifert, G., *75
 Seligson, David, *243
 Sellman, J. C., *486
 Seltzer, Holbrook S., 417-424
 Serbin, Richard A., *401
 Serif, George S., 112-115, *329
 Shepherd, Herndon G., Jr., *329
 Sheppe, W. M., 192-195
 Shields, Charles E., *243
 Shigeta, Y., *74, *76
 Shlevin, Edmund L., *326
 Shohl, Jane, *76
 Shreeve, Walton W., *401
 Siegner, Allan W., *330
 Sigal, Max V., Jr., 7-13
 Silver, Henry K., *329
 Silverman, Melvin, *320
 Silverstein, Joseph N., *480
 Simon, Julius, *486
 Simpson, John R., *329
 Simpson, M. E., *325
 Simpson, W. W., *157
 Siperstein, Marvin D., *161, *243
 Sirek, Anna, 284-288
 Sirek, Otakar V., 284-288
 Skillern, Penn G., *487
 Skillman, Thomas G., 274-278
 Sklaroff, Stanley A., *400
 Skom, Joseph H., *329
 Sloper, J. C., *487
 Smid, L. J., 100-104
 Smith, Bette-Barron, *161
 Smith, G. Howard, *160, *161
 Smith, Walter L., 417-424
 Smyrl, S., 179-188
 Sobel, Gerald W., *329
 Sokal, Joseph E., *161, *487
 Solomon, Fredric, 45-50
 Somogyi, Michael, *329, *330
 Soothill, John F., 251-256
 Sotto, Luciano S., *330
 Splitter, S., 179-188
 Staffurth, J. S., *238
 Stare, Fredrick J., *405
 Staub, A., *72
 Staub, M., *330
 Stearns, Samuel, 379-382
 Steele, R., 105-111, *320
 Steenstrup, O. R., *399

Steiner, Donald F., *242
 Steiner, Paul E., 298-306
 Steiness, Ib, *487
 Stempfel, Robert S., Jr., *162
 Stetten, DeWitt, Jr., 307-314
 Stewart, Charles J., 112-115, *329
 Stone, Martin L., *405
 Strickland, S. Clyde, *70
 Strindberg, B., *162
 Ström, Loris, *484
 Struck, William A., *72
 Stunkard, Albert J., 371-378
 Stutman, Leonard J., 189-191
 Sullivan, William T., *483
 Sutherland, Earl W., *326
 Suzuki, Kozo, *483
 Swanson, Heidi E., *332
 Symons, C., *159
 Szanto, Paul S., *324
 Szenas, P., *330
 Szucs, M. M., *244
 Szucs-Verbiest, M., *238

T

Tagnon, R., *330
 Talmage, David W., *329
 Tanner, Donald C., *242
 Taylor, K. W., *243, *327
 Terman, Louis A., *330
 Terner, Charles, *76
 Test, C. E., 298-306
 Thomas, Caroline Bedell, *330
 Thompson, John S., *331
 Thompson, Marilyn M., *405
 Thorn, George W., 337-349
 Tidball, M. E., *484
 Tietze, Frank, 307-314
 Tipton, Dale L., Jr., *479
 Tolstoi, Edward, *244
 Tomsovic, Edward J., *331
 Tornow, Abraham M., 1-6
 Traisman, Howard S., 289-293, *404
 Trounce, J. R., 174-178
 Tupikova, Natalia, 298-306
 Tybergheim, Jean M., *161
 Tyler, F. H., *486

U

Unger, Roger H., *487
 Unno, H., *76

V

Vallance-Owen, J., *76, *244
 Vallee, B. L., *76
 Vance, Vernon K., *73
 van Buchem, F. S. P., 100-104
 Vander, John B., *405
 van der Geld, H., *239
 Van Itallie, Theodore B., 94-99, 226-231
 Vannas, S., *483
 Venning, E. H., *157
 Verner, John V., *161
 Vincent, Thomas N., 442-449
 Vinke, B., 100-104
 Vitti, Trieste, 57-62
 Volk, Bruno W., *76, 128-131, 294-297, *325, *484
 Voss, Virgil H., *331

W

Wada, M., *74, *76
 Waddell, William R., *405
 Wade, Leo, 143-148
 Wagner, Martin J., *488
 Walker, G., 179-188
 Walker, Robert S., *488
 Wall, J. S., 105-111, *320
 Wang, Ian, *242, *324
 Weaver, Neill K., *488
 Weisenfeld, Shirley, 116-127, *162
 Weiss, Daniel M., *74
 Weiss, Harold S., *331
 Weller, Charles, *331
 Wells, Ronald, *77, *244
 Werk, Emile E., Jr., *326
 West, Edward S., *479
 West, Kelly M., 22-28, *162, *241
 Westerink, D., *160
 Wheeler, P., 179-188
 Whipple, N., *72
 White, Priscilla, *71
 White, Thomas T., *488
 Whitehouse, Fred W., *331
 Wick, Arne N., *77, 112-115, *329
 Widdas, W. F., *158
 Wildhack, Rudolf, *331
 Wilgram, G. F., 205-210
 Wilhelm, C. M., *74
 Wilkerson, Hugh L. C., *332
 Wilkins, Lawson, *162
 Willebrands, A. F., *160
 Williams, R. D. Brooke, *488
 Williams, Robert H., *161, *242, *326, *332
 Williams-Ashman, H. G., *77, *332
 Williamson, Joseph R., *332
 Wilson, J., *402
 Wilson, William D., 36-44
 Winegrad, Albert I., *332
 Winter, M., *162
 Wiseman, M. H., *162
 Wolff, Harold G., 358-362
 Wolfson, S. K., Jr., *77, *332
 Wood, Dorothy Antonia, 22-28
 Woodward, H., Jr., 432-437
 Worm, M., *77
 Wright, Lemuel D., *70
 Wright, Paul A., *488
 Wright, P. H., *70

Y

Yalow, Rosalyn S., *157
 Yam, Tan Bock, *77
 Yang, Yong H., *488
 Yerganian, George A., *403
 Yoshida, T., *74, *76
 Young, F. G., *160

Z

Zetterström, R., *77, *162
 Zimmerman, George R., *320
 Zinke, Myra R., 1-6

DIABETES: VOLUME 8 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-166

May-June, 167-250

July-August, 251-336

September-October, 337-416

November-December, 417-496

